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Protective measures against malaria during pregnancy are rarely initiated until 
the second trimester, leaving at-risk pregnancies unprotected from malaria infection in 
the critical first trimester.  
This dissertation details the first large-scale multi-site study of malaria in the first 
trimester, and is nested within the NICHD Global Network’s trial of low-dose aspirin for 
the prevention of preterm delivery in nulliparous women with a singleton pregnancy (the 
ASPIRIN Trial). This dissertation aimed to (1) characterize the factors which increase 
the likelihood of malaria in the first trimester and (2) estimate the causal effects of 
malaria in the first trimester on adverse maternal and birth outcomes. 
Aim 1 first calculated the parasite prevalence in the first trimester and found that 
among 485 Congolese women it was 62.9%, among 677 Kenyan women it was 37.8%, 
and among 351 Zambian women it was 6.3%. Kenyan women younger than 20 years 
old were more likely to have malaria in the first trimester (prevalence difference (PD) = 
0.17 [99% confidence interval (CI): 0.07, 0.26]), and across all three study countries, 




associated with higher prevalence of malaria in the first trimester (summary PD = 0.09 
[99% CI: 0.01, 0.17])  
Aim 2 found higher prevalences of preterm delivery (adjusted PD (aPD) = 0.06 
[99% CI: -0.04, 0.16]) and low birth weight (aPD = 0.07 [99% CI: -0.03, 0.16]) among 
Congolese women with malaria in the first trimester, and higher prevalence of anemia in 
late pregnancy among Kenyan (aPD = 0.05 [99% CI: -0.06, 0.17]), Zambian (aPD = 
0.07 [99% CI: -0.12, 0.36]), and Congolese (aPD = 0.04 [99% CI: -0.09, 0.16]) women 
who had malaria in the first trimester.  
These findings suggest that malaria in the first trimester is very common in areas 
of high transmission, and is associated with higher prevalences of preterm delivery and 
low birth weight in an area of high transmission, and with higher prevalence of anemia 
in late pregnancy at all three sites. These results suggest a need to improve strategies 
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CHAPTER I: SPECIFIC AIMS 
Chapter 1  
In malaria-endemic countries, an estimated 1 in 4 women are infected with 
malaria during their pregnancy, and this infection can cause maternal anemia, preterm 
birth, stillbirth, and low birth weight.1 Despite these adverse effects, malaria in 
pregnancy is difficult to identify and thus treat because pregnant women frequently have 
parasite densities below the detection limit of commonly available diagnostic tools. In 
addition, prevention strategies including the use of intermittent preventive therapy in 
pregnancy with sulfadoxine-pyrimethamine (IPT-SP) and the use of insecticide-treated 
nets (ITNs) are challenging to initiate for women early in their pregnancy.2 IPT-SP is not 
recommended in the first trimester of pregnancy because of potential teratogenic 
effects, and most pregnant women do not use ITNs because of discomfort associated 
with sleeping under the ITN, difficulties in hanging the net, and/or lack of ownership of 
ITNs.3–8 These challenges to diagnosing, treating, and preventing malaria leave women 
under-protected from malaria in the first trimester. 
Despite the difficulties in treatment and prevention of malaria, the first trimester 
might represent a critical time for intervention to prevent the negative consequences of 
malaria in pregnancy. Placentation is particularly sensitive to pathology in the first 
trimester, and malaria in early pregnancy could inhibit trophoblast invasion and cause 




early pregnancy was associated with a negative impact on placental vascular 
development and consequent pregnancy outcomes.11,12  
Changes in placental vascularity would be even more pronounced among 
primigravidae and among women living in high malaria transmission areas.11 Women in 
their first pregnancy are particularly unprotected from malaria, as women naturally 
acquire resistance to malaria in pregnancy in successive pregnancies through the 
development of antibodies that inhibit binding of Plasmodium falciparum-infected 
erythrocytes to the placenta.12,13 Thus, primigravid and nulliparous women are most 
vulnerable to chronic placental infection, which is associated with low birth weight and 
maternal anemia.13–17 Although malaria in the first trimester could lead to adverse 
effects on maternal and birth outcomes, especially among women in their first 
pregnancy, research in this under-protected period is limited because most studies are 
limited to observations in the second trimester when women begin receiving antenatal 
care (ANC).  
The current proposal is the first large-scale multi-site study of malaria in the first 
trimester, and is nested within the NICHD Global Network’s trial of low-dose aspirin for 
the prevention of preterm delivery in nulliparous women with a singleton pregnancy (the 
ASPIRIN Trial).18,19 As the ASPIRIN trial specifically enrolled nulliparous women in the 
first trimester, this sub-study leveraged this opportunity to characterize predictors and 
estimate causal effects on maternal and birth outcomes of malaria in the first trimester. 
At enrollment, three dried blood spots were obtained from 1,513 pregnant women 
in the three sub-Saharan African sites of the Global Network (Democratic Republic of 




Plasmodium falciparum infection, and then linked these results to data collected from 
ASPIRIN trial participants. The overall objective of this study was to characterize 
predictors of malaria in the first trimester, and estimate causal effects of malaria in the 
first trimester on adverse maternal and birth outcomes. 
AIM 1: Characterize the factors which are associated with increased 
likelihood of malaria in the first trimester. Limited research studying malaria in early 
pregnancy suggest that predictors of malaria in early and late pregnancy include 
maternal age, socioeconomic status, and seasonality.9,20–23 The ASPIRIN trial collected 
data on potential predictors including age, height, body-mass index (BMI), education, 
socioeconomic status, and seasonality. We characterized the factors which are 
associated with increased likelihood of malaria in the first trimester. We hypothesized 
that lower overall educational attainment (no secondary education) was associated with 
increased likelihood of malaria in the first trimester. 
AIM 2: Estimate the causal effect of malaria in the first trimester on adverse 
maternal and birth outcomes. While the effect of malaria in the second and third 
trimester on adverse birth outcomes has been well established, the effects of malaria in 
the first trimester are still unclear. The ASPIRIN trial collected data on adverse maternal 
outcomes including anemia in late pregnancy and hypertensive disorders in pregnancy, 
and on birth outcomes including preterm birth, small for gestational age, low birth 
weight, and perinatal mortality. We estimated the causal effect of malaria in the first 
trimester on adverse maternal and birth outcomes. We hypothesized that malaria in the 





This sub-study of the ASPIRIN trial provides a unique opportunity to study 
nulliparous pregnant women in the DRC, Kenya, and Zambia to address the important 
dearth in knowledge on the predictors and effects on maternal and birth outcomes of 
malaria in the first trimester. Understanding predictors of malaria in the first trimester 
could lead to better prevention strategies. Estimating the causal effect of malaria in the 
first trimester on maternal and birth outcomes will inform policy efforts to shift ANC to 
begin in the first trimester, and drive research developments on prophylactic malarial 









CHAPTER II: BACKGROUND 
Chapter 2  
Malaria 
Malaria is a serious global health issue with an estimated 228 million cases 
worldwide causing 411,000 deaths in 2018.24 Malaria is an acute febrile illness that is 
caused by the Plasmodium parasite and is transmitted by the bites of an infected 
Anopheles mosquito.24  
There are five species of Plasmodium infect humans, and the two main species 
that contribute to malaria infection are Plasmodium falciparum and Plasmodium vivax.25 
P. falciparum is the predominant species in sub-Saharan Africa, while P. falciparum and 
P. vivax coexist in Southeast Asia, Western Pacific, and South America.25 In 2018, P. 
falciparum caused 99.7% of estimated malaria cases in sub-Saharan Africa and is the 
most deadly malaria parasite globally.24 
Malaria can lead to severe illness including anemia, acute pulmonary edema, 
hypoglycemia, and can lead to death.24,26 To prevent malaria, the World Health 
Organization (WHO) supports the use of insecticide-treated nets/long-lasting 
insecticide-treated nets (ITNs/LLINs) and indoor residual spraying (IRS).2 To prevent 
malaria in pregnancy, WHO recommends intermittent preventive therapy during 
pregnancy with the antimalarial drug sulfadoxine-pyrimethamine (IPT-SP) monthly 




Africa bears a disproportionate malaria burden with 93% of global malaria cases 
and 94% of global malaria deaths in 2018 (an estimated 213 million cases and 380,700 
deaths caused by malaria).24 Almost all of the estimated 213 million cases of malaria in 
Africa are caused by Plasmodium falciparum.24 Nearly 85% of malaria deaths globally in 
2018 occurred in 21 countries including the Democratic Republic of the Congo, Kenya, 
and Zambia.2 
Malaria in the Democratic Republic of the Congo, Kenya, and Zambia 
The Democratic Republic of the Congo (DRC) accounted for 12% of the malaria 
cases and 11% of the malaria deaths worldwide in 2018 (about 27 million cases and 
45,000 deaths).2 In the DRC, malaria transmission occurs throughout the year.2 In 2017, 
97% (78.9 million) of the population lived in an area of high malaria transmission (>1 
case per 1000 population) and 3% (2.4 million) of the population lived in an area of low 
malaria transmission (0-1 case per 1000 population).27 In the provinces of Nord and Sud 
Ubangi, located in the Northwest of the DRC, malaria transmission is high and ranges 
from 10 to over 300 confirmed cases of malaria per 1000 population (Figure 2.1).27 
 
Figure 2.1: P. falciparum malaria cases in the DRC, 2017  
In Nord and Sud Ubangi, located in the Northwest of the DRC, malaria transmission is 




Figure obtained from the WHO’s Country Profiles for Malaria: Democratic Republic of 
the Congo.27 
 
Kenya accounted for 2% of the malaria cases and 3% of the malaria deaths 
worldwide in 2018 (about 3.6 million cases and 12,000 deaths).2 In 2017, about 70% 
(34.9 million) of the population lived in an area of high malaria transmission (> 1 case 
per 1000 population), and about 30% (14.8 million) of the population lived in an area of 
low transmission (0-1 case per 1000 population).28 Malaria transmission can be as high 
as 300 cases per 1000 population.28 In western Kenya in the counties of Busia, 
Bungoma, and Kakamega, malaria transmission is high and ranges from 10 to over 300 
confirmed cases of malaria per 1000 population (Figure 2.2).28 In this Lake Victoria 
region, malaria prevalence is 27% and ITNs are the primary prevention tool.29  
 
Figure 2.2: P. falciparum malaria cases in Kenya, 2017  
In the counties of Busia, Bungoma, and Kakamega, located in western Kenya, malaria 
transmission is high and ranges from 10 to over 300 confirmed cases of malaria per 
1000 population. Figure obtained from the WHO’s Country Profiles for Malaria: Kenya.28 
 
Zambia accounted for 1% of the malaria cases and 2% of the malaria deaths 
worldwide in 2018 (about 2.7 million cases and 7,500 deaths).2 In Zambia, malaria 




area of high malaria transmission (>1 case per 1000 population), and malaria 
transmission occurs throughout the year.30 In the districts of Kafue and Chongwe, 
located in southern Zambia, malaria transmission ranges from 10 to 50 confirmed cases 
of malaria per 1000 population (Figure 2.3).30 
 
Figure 2.3: P. falciparum malaria cases in Zambia, 2017 
In the districts of Kafue and Chongwe located in southern Zambia, malaria transmission 
ranges from 10 to 50 confirmed cases of malaria per 1000 population. Figure obtained 
from the WHO’s Country Profiles for Malaria: Zambia.30 
 
A summary of the WHO recommended malaria prevention strategies (i.e., ITNs, 
IRS, and IPT-SP) and their implementation in DRC, Kenya, and Zambia is presented in 
Table 2.1.2,27,28,30 
Table 2.1: Summary of malaria prevention strategies in DRC, Kenya, and Zambia  
 DRC Kenya Zambia 
Free distribution of ITNs  since 2006 since 2006 since 2005 
Population with access to ITN (%) 71% 74% 79% 
IRS recommended  since 2007 since 2003 since 1964 
People protected by IRS (n) 111,735 1,833,860 6,436,719 
IPT-SP used  since 2004 since 2001 since 2001 
Pregnant women with 3+ doses 
IPT-SP (%) 





Malaria in pregnancy 
In sub-Saharan Africa, an estimated 39 million pregnancies occurred in 2018, of 
which 29% or 11 million pregnancies were exposed to malaria infection.2 Malaria in 
pregnancy is associated with negative health outcomes including maternal anemia, low 
birth weight, preterm birth, and fetal loss.13 P. falciparum-infected red blood cells 
sequester in the placenta, while P. vivax-infected red blood cells have not yet been 
documented to sequester in placenta.25 P. falciparum and P. vivax can lead to 
pregnancy complications, but the consequences of infection in pregnancy with P. vivax 
is generally less severe.25  
Malaria in pregnancy in DRC, Kenya, and Zambia 
To prevent malaria in pregnancy, the World Health Organization recommends 
prompt diagnosis and treatment of malaria, IPT-SP, and ITNs/LLINs.2 
Despite moderate coverage of four or more antenatal care (ANC) visits and of 
use of three or more doses of IPT-SP during pregnancy as recommended by WHO, the 
DRC has one of the highest burdens of malaria in pregnancy worldwide.2,31–33 Each 
year, 3.5 million pregnancies are at risk of malaria infection, and an estimated 1 million 
births are affected by malaria.2,31–33 
In Kenya, there is moderate coverage of four or more ANC visits, but use of three 
or more doses of IPT-SP is low.2 ITNs/LLINs are distributed free of charge, and are 
distributed through antenatal care visits, well baby clinics, and through mass 
campaigns.2  
In Zambia, there is moderate coverage of both four or more ANC visits and of 




Definitions of malaria in pregnancy 
Malaria in pregnancy is defined as a Plasmodium infection (primarily P. 
falciparum but includes P. vivax, etc.) detected at any point in pregnancy. Most research 
in malaria in pregnancy recruit women starting at their first ANC visit which mostly 
occurs in the second trimester. Thus, most malaria in pregnancy research studies 
infections from the second trimester onwards.  
Malaria in early pregnancy in the literature is generally defined as a Plasmodium 
infection detected in the first half of pregnancy. Malaria in the first trimester is a more 
restrictive definition and is defined as a Plasmodium infection detected in the first 
trimester (<14 weeks of gestational age). 
Parity is defined as the number of live and stillbirths, and does not include 
miscarriages.34 Nulliparous women have never delivered a fetus that has reached the 
age of viability; thus, women are nulliparous until they deliver a stillbirth or a live birth.34 
Primiparous women have delivered their first stillbirth or live birth, and multiparous 
women have delivered more than one stillbirth or live birth.34 
Gravidity is defined as the number of previous pregnancies, and includes 
miscarriages.34 Primigravidae women are pregnant for the first time, and multigravidae 
women have been pregnant more than once.34  
Measuring malaria in pregnancy 
In non-pregnant women, malaria parasites are found in the peripheral blood 
circulation and sequester to endothelial cells.35,36 In pregnant women, parasites can be 
found in peripheral blood and placental circulation, and sequester in the placenta along 




parasite protein expressed on the surface of the infected red blood cell.12 This protein 
adheres to chondroitin sulfate A (CSA) which is expressed on the syncytiotrophoblast 
(the layer of cells in the placenta lining the maternal blood spaces), and thus this 
parasite protein is called VAR2CSA (variant surface antigen mediating adherence to 
chondroitin sulfate A).12 By expressing a different antigen variant VAR2CSA, the P. 
falciparum parasites sequester in the intervillous spaces of the placenta (known as 
placental malaria) and avoid splenic clearance.13,36,37 Because P. falciparum parasites 
can accumulate in the placenta but be absent or undetectable in peripheral blood, 
diagnosing malaria in pregnancy is difficult.36,37 These undetectable low parasite 
densities may be asymptomatic but can still have serious negative health impacts on 
the mother and her fetus.3,37 
Tools used to measure malaria in pregnancy vary depending on whether it is 
placental or peripheral malaria. Placental malaria can be measured through placental 
blood microscopy and placental histology.17,38,39 Peripheral parasitemia can be 
measured through blood smear light microscopy, rapid diagnostic tests (RDTs), and 
molecular detection techniques including polymerase chain reaction (PCR).40,41 The 
sensitivity and specificity of tests are based on parasite density, with lower sensitivity at 
lower parasite densities.36 
Placental parasitemia 
Placental malaria is defined as malaria parasites or hemozoin pigment (a 
breakdown product of hemoglobin formed from digestion by blood-feeding parasites 
including Plasmodium) present in placental blood or tissue, and can be measured 




microscopy identifies through light microscopy microscopic parasite infections in 
placental blood collected from the intervillous spaces of the placenta.36,42,43 However, 
the gold standard for placental malaria is histological observation of infected 
erythrocytes (red blood cells) or hemozoin pigment in the intervillous spaces of the 
maternal side of the placenta.17,36 These placental histology slides are classified based 
on whether there are parasites in the placenta (active infection), parasites and pigment 
in the placenta (active chronic infection), only pigment in the placenta (past infection), or 
no parasites or pigment in the placenta (no infection).36 
P. falciparum-infected erythrocytes avoid splenic clearance by sequestering in 
the placenta.17 This sequestration of P. falciparum parasites in the placenta can occur in 
the absence of detectable peripheral parasitemia, making detection of malaria in 
pregnancy and consequent treatment difficult.17,44 Placental histology is more sensitive 
than placental and peripheral blood film examination, and is the gold standard for 
placental malaria.17,37 However, histology is not suitable for all situations or study 
designs as it (and placental blood) can only be examined after delivery and does not 
provide information when in pregnancy malaria infection is the most harmful to birth 
outcomes.36,39,43 Thus, peripheral blood infection is used to infer placental infection 
before delivery, and is the only way to detect malaria infection during pregnancy.36,37  
Peripheral parasitemia 
Peripheral parasitemia in pregnancy is defined by the presence of P. falciparum 
parasites in the peripheral blood with or without placental infection.36 In high malaria 
transmission areas, the parasitemia levels among pregnant women can fluctuate and be 




malaria parasites in peripheral blood does not exclude infection or sequestration of 
parasites in placental tissue.3,43 While using peripheral samples to detect malaria may 
not be the most accurate method, it is the only method possible during pregnancy (i.e., 
before delivery).43 
The main methods for detecting peripheral blood malaria parasitemia in pregnant 
women are blood smear light microscopy, RDTs, and molecular detection.40,41 These 
diagnostic methods vary in accuracy based on the lower limits of detection of P. 
falciparum parasites, and generally the lower limits of detection are highest for RDTs, 
lower for trained and well-equipped light microscopy, and lowest for PCR.45 
Measuring peripheral parasitemia using light microscopy 
Malaria can be defined using light microscopy as a peripheral blood smear 
positive for blood-stage asexual parasites.37,46 Venous or capillary blood is collected to 
make thick and thin smears, and are stained and examined microscopically to detect 
the presence of malaria parasites.36 This blood smear light microscopy conducted by an 
experienced technician with appropriate equipment has a detection threshold of 15 
parasites per uL of blood.3 This threshold is well below the density threshold where 
patients present with symptoms, and therefore is sufficient for those pregnant women 
presenting with symptoms.3,5 However, most infections during pregnancy are 
asymptomatic with low parasite densities and therefore are often not detected by 
microscopy.3,5 These submicroscopic infections (i.e., parasitemia not detected by 
microscopy but detected through more sensitive methods) have been associated with 




sensitivity of light microscopy prevents identification of pregnant women who may need 
malaria treatment to prevent further harm to the mother and the fetus.3 
Measuring peripheral parasitemia using rapid diagnostic tests 
An alternative to peripheral blood microscopy with reasonable accuracy are 
RDTs, a more recent method that is quick and easy to use in inaccessible areas.13,36 
While the parasite threshold for RDTs is higher at 200 parasites per uL compared to 
that of microscopy at 15 parasites per uL, RDTs do not need trained technicians with 
appropriate equipment.3,5 RDTs detect parasite antigens in the blood using specific 
monoclonal antibodies through immunochromatographic approaches.13,36 These RDTs 
can detect soluble Plasmodium antigens including histidine-rich protein 2 (HRP2), 
adolase, and Plasmodium falciparum lactate dehydrogenase (pfldh).13,36 Because RDTs 
detect circulating parasite antigens such as HRP2 even when the parasite is 
sequestered in the placenta, RDTs could be useful in diagnosing placental malaria in 
the absence of peripheral infection.5,36,37 
The quality of the RDTs, especially HRP2-based tests, can be high in accuracy 
and stability.36 However, potential limitations to the sensitivity of HRP2-based tests 
include antigenic variation or gene deletions of HRP2.37 In addition, RDTs lack the 
sensitivity needed to detect the low-density peripheral parasitemia found in pregnant 
women.3,47 Subpatent infections (i.e., parasitemia not detected by RDTs but detected 
through more sensitive methods) generally include submicroscopic infections and have 
been suggested by some researchers but not others to lead to negative birth 
outcomes.4,5 RDT-based screening and treatment strategies that have been popularized 




method to allow a more comprehensive understanding of the burden of malaria (both 
microscopic/patent and submicroscopic/subpatent infections) that is not readily 
available in low and middle-income countries is molecular detection methods such as 
PCR.38,47 
Measuring peripheral parasitemia using polymerase chain reaction 
An alternative method for diagnosing malaria infection is PCR which detects 
nucleic acid.36 PCR is the most sensitive detection method of malaria (both peripheral 
and placental malaria) and has allowed studies of low-density P. falciparum 
parasitemia, including studies determining malaria in pregnancy as pregnant women 
frequently have low levels of parasitemia.36,41,47 Using standard PCR methods and 
genomic nucleic acid extracted from dried blood spots, researchers can detect more 
sensitive estimates of maternal malaria infection than microscopy or RDTs.37,40,48,49 
PCR can detect parasite densities as low as 1 parasites per uL of peripheral blood.50 
However, PCR is time consuming and requires specialized laboratories and trained 
staff, and therefore is not available for routine diagnosis in resource-limited areas.36,37,41  
PCR is able to detect at very low levels parasite nucleic acids, but these nucleic 
acids could be residuals from a viable parasite or gametocyte or a non-viable 
sequestered parasite.36 In addition, PCR has been shown to have similar difficulty in 
diagnosing active placental infections during pregnancy as other methods that use 
peripheral blood. Use of peripheral blood PCR to diagnose placental malaria failed to 
detect more than half of the active placental infections in one study, likely because of 
sequestration of P. falciparum parasites in the placenta and evasion of spleen clearance 




using peripheral blood PCR.43 In addition, as placental infections cannot be determined 
until after delivery, the best approximation is using peripheral blood to detect malaria 
infection.36,37,43 Finally, PCR is able to detect parasitemia below the thresholds of 
microscopy and RDTs, but the clinical relevance of these submicroscopic/subpatent 
infections are uncertain.36,45  
Measuring peripheral parasitemia using polymerase chain reaction: subpatent and 
submicroscopic infections 
 
Subpatent infections are defined as peripheral blood infections below the 
detection limit of RDTs, but are detected through more sensitive methods such as 
PCR.41 Subpatent infections are very common in areas of high malaria transmission.41 
In all malaria transmission settings, adults have the highest proportion of subpatent 
infections.49 
The health consequences of subpatent infections are unclear.41,45 Subpatent 
infections have been associated with poor maternal and birth outcomes including 
maternal anemia in pregnancy and lower birth weight.45 However, in a study among 
pregnant women living in an area of high malaria transmission in Malawi, untreated 
subpatent infections were not associated with negative health outcomes for the mother 
or child.45 Researchers have suggested that these higher-density subpatent infections 
may bolster the maternal immunity response to parasites that sequester in the placenta, 
mitigating adverse outcomes.45 
Submicroscopic infections cannot be identified through microscopic examination 
of a blood smear, and can only be identified through more sensitive methods including 
molecular detection.38 Submicroscopic peripheral malaria infections are defined as 




not through blood smear.38 Submicroscopic placental malaria infections are defined as 
placental parasites detected through more sensitive methods but not through 
histology.38 RDTs generally have a higher limit of detection of parasites (about 200 
parasites per uL of peripheral blood) compared to microscopy (generally lower limit of 
about 40-50 parasites per uL of peripheral blood, can be as low as 15 parasites per 
uL)3,45; thus by parasite threshold, subpatent infections generally include 
submicroscopic infections. 
Submicroscopic malaria infections may be significant contributors to malaria 
transmission, and may predominate in low malaria transmission settings.49 The 
prevalence of submicroscopic infections varies depending on transmission intensity, 
and in a wide range of transmission settings, submicroscopic infections in pregnancy 
have been shown to be several times more common than microscopic infections in 
pregnancy.38,49 In some settings, prevalence of submicroscopic malaria infections in 
pregnancy has been as high as 55%.51 
Submicroscopic infections are likely more clinically relevant during pregnancy, as 
any density of malaria parasitemia could lead to negative health outcomes for the 
mother and her fetus.51 However, the clinical significance of these submicroscopic 
infections is still a matter of some debate.36,45 First, as PCR measures parasite nucleic 
acids, use of PCR to diagnose placental malaria could instead be detecting non-viable 
sequestered parasites.36 In addition, pregnant women can spontaneously clear 
submicroscopic infections.38 Some researchers have suggested that host immunity 
inhibits parasites to these low-level densities, and that women who are able to control 




outcomes associated with placental malaria infections.43,51 In contrast, other studies 
have found that women who have submicroscopic malaria infections have a higher risk 
of maternal anemia and low birth weight compared to women with no infections, but a 
lower risk when compared to women with microscopic malaria infections.17,36–38 In 
addition, submicroscopic malaria infections detected at delivery increased the risk of 
stillbirth.52 These low-density infections could be recently acquired infections that if left 
untreated, could reach microscopic-detectable densities and lead to more serious 
negative health outcomes.36,51  
Because submicroscopic infections are undetectable through standard 
techniques and are often asymptomatic, they are frequently untreated through routine 
ANC despite potentially leading to negative maternal and infant health outcomes.36,51,52 
Among primigravidae, submicroscopic infections but not microscopic infections were 
associated with higher risk of low birth weight, potentially because microscopic 
infections were immediately treated while submicroscopic infections were not.4 These 
untreated and prolonged submicroscopic infections consequently can lead to negative 
health outcomes.4,38  
Women who are infected with malaria before pregnancy are more likely to be 
infected while pregnant, suggesting that some of the malaria infections detected during 
pregnancy were acquired before pregnancy.21,53 These malaria infections include 
infections undetectable through microscopy and can persist through conception until the 
first ANC visit when they are treated through IPT-SP.38,53 These untreated infections, 





Submicroscopic infections are very common at the first ANC visit, suggesting a 
need for earlier treatment and protection from malaria in order to prevent malaria in 
pregnancy.38 This burden of submicroscopic or subpatent malaria infection particularly 
affects women in their first trimester of pregnancy as they are excluded from mass drug 
administration programs and are often treated based on the RDT malaria result.41 
Therefore, these undetected and untreated infections among women in their first 
trimester of pregnancy can support malaria transmission and undermine malaria 
elimination strategies.41 Many malaria interventions such as distribution of ITNs and 
IPT-SP are carried out once women seek ANC which is typically in the second or third 
trimester.38 However, by this point, peripheral and placental infections can already be 
established leading to negative birth outcomes.38 We plan to determine if peripheral 
infections detected in the first trimester lead to negative maternal and birth outcomes. 
Protective measures of malaria in pregnancy 
To prevent malaria in pregnancy, the WHO recommends prompt diagnosis and 
treatment of malaria, IPT-SP and ITN/LLINs to prevent malaria in pregnancy.2 However, 
these strategies are challenging to initiate for women early in their pregnancy and 
habitually leave women unprotected from malaria in the first trimester.  
Diagnosing malaria in pregnancy is difficult as pregnant women frequently have 
low levels of parasitemia that are asymptomatic and are below the detection limit of 
common diagnostic tools such as microscopy and RDTs.3–6 These submicroscopic or 
subpatent malaria infections are found frequently in women in their first trimester of 
pregnancy, and may be acquired before conception.8,21,53 As treatment of women in 




treated for these potentially undetectable infections.41 Intermittent preventive therapy 
with sulfadoxine-pyrimethamine (IPT-SP) can clear these submicroscopic infections, but 
is contraindicated during the first trimester because of potential teratogenic effects; thus, 
women with submicroscopic or subpatent infections in their first trimester are 
unprotected from these potentially asymptomatic infections that can still cause placental 
pathology and negative birth outcomes.7,23,38,54 
The WHO recommends the use of IPT-SP as early as possible in the second 
trimester, and at each scheduled ANC visit at least one month apart.13 SP clears both 
existing drug-sensitive parasites and prevents incident infections.40 However, SP is 
contraindicated during the first trimester because of potential teratogenic effects.7,23,54 
Specifically, SP is a folate antagonist which is associated with neural tube defects, and 
as neural tube closes during the first trimester, SP is contraindicated during this time.7 
While use of SP only after the first trimester minimizes the risk of teratogenicity, it 
means that malaria infection during trophoblast invasion or placentation is not 
addressed by IPT-SP.55 Therefore, women in their first trimester are still vulnerable to 
malaria infection obtained during early pregnancy or prior to conception despite use of 
IPT-SP. 
ITNs can prevent malaria infection during all stages of pregnancy, including this 
vulnerable time of preconception and early pregnancy.56 ITNs can substantially reduce 
the risk of malaria in pregnancy, and use of ITNs have been shown to reduce low 
birthweight, miscarriage, stillbirths, placental parasitemia, and neonatal and child 
mortality.56,57 They are the most well-known and preferred method to prevent malaria in 




40% of pregnant women in sub-Saharan Africa slept under an ITN, and less than 60% 
of pregnant women who own an ITN use them regularly.8,58 Many pregnant women in 
malaria-endemic settings do not use ITNs because of discomfort associated with 
sleeping under the ITN, insufficient motivation to use the ITN, and lack of ownership of 
ITNs.3–8 In addition, women before and during their first pregnancy use ITNs 
substantially lower than women of higher parities; the median estimate of ITN use 
immediately prior to the first pregnancy was 25% while prior to subsequent pregnancies 
was above 40%.8 Many pregnant women obtain their first ITNs at their first ANC visit 
which often occurs in the second trimester, and thus are not protected prior to their first 
ANC visit in their first pregnancy (i.e., during their first trimester of their first 
pregnancy).21,23 Overall then, nulliparous women are rarely protected by ITNs prior to or 
during their first trimester of pregnancy. 
These current preventative strategies of diagnosing and treating, IPT-SP, and 
ITNs are frequently not used during the first trimester, leaving women unprotected from 
malaria during this period. In addition to protective measures, malaria in pregnancy is 
impacted by transmission intensity and the immunity of the mother. 
Impact of transmission intensity and immunity on malaria 
Malaria transmission intensity has serious implications on the acquisition of 
natural immunity to malaria.59 Through repeated exposure to the P. falciparum parasite, 
individuals in moderate to high malaria transmission areas develop protection against 
malaria.26,60 With subsequent exposures, they build immunity, first to severe malaria, 
then illness with malaria, and ultimately immunity against microscopic-detectable 




exposure against different parasite isolates and reduces the frequency and density of 
parasitemia.44 As a consequence, in areas of high malaria transmission, morbidity and 
mortality from malaria is highest in early childhood and asymptomatic malaria is 
common in older children and adults in high transmission areas.26,60 
Individuals in low, unstable, or seasonal malaria transmission areas have 
infrequent exposure to infection, and therefore have low immunity.61 Without this 
acquired protection, infection with malaria often leads to symptomatic disease and can 
progress to severe malaria with serious negative health outcomes regardless of 
age.13,26,61 However, in all transmission settings, women who are pregnant are at higher 
risk of malaria infection.44 
Impact of pregnancy on risk of malaria 
The susceptibility of women to malaria infection increases in pregnancy because 
immunomodulation occurs during pregnancy as the immune system changes to accept 
the fetal allograft.44 This increased susceptibility is partially due to the P. falciparum 
parasite avoiding splenic clearance and sequestration in the placenta.41,62,63 Infection 
during pregnancy also decreases the level of specific antibodies, increasing the risk of 
complications due to malaria in pregnancy.64 
Even in areas of high malaria transmission where pregnant women have 
acquired a partial immunity to malaria, the risk of malaria infection increases when a 
woman becomes pregnant.41,59,65 Pregnant women from all transmission settings 
frequently experience asymptomatic peripheral parasitemia and are at much higher risk 
of severe disease compared to non-pregnant women.59,65 However, even in the 




placenta can be heavily infected with P. falciparum parasites, consequently leading to 
reduced birthweight.2,66–68 The risk of delivering a low birthweight infant doubles when 
women have placental malaria infection.1,26 Asymptomatic malaria in pregnancy can 
also lead to severe maternal anemia and infant mortality.1,13,26,69  
The intensity of malaria transmission likely affects the relationship between 
maternal antibody responses and malaria in pregnancy.70,71 Pregnant women living in 
areas of moderate to high malaria transmission may develop broader antibody 
responses to P. falciparum infection earlier in pregnancy compared to pregnant women 
living in areas of low or seasonal malaria transmission.70,71 
Most research on malaria in pregnancy is from areas of high transmission, and a 
review of the literature from 1985 to 2000 found the prevalence of malaria in pregnancy 
ranged from 10-65% among all gravidae and a median prevalence of 27.8%.1,63,72 As 
the transmission intensity of malaria decreases, the prevalence of malaria in pregnancy 
also decreases.13,73 However, in areas of lower transmission intensity, the malaria-
specific antibodies also wane, leading to increased parasite burden and negative health 
outcomes during any malaria infection.13,73 
In these low or unstable malaria transmission areas, malaria in pregnancy is still 
a large burden and the estimated prevalence of peripheral malaria infection was 13.7%, 
and the median placental malaria prevalence was 6.7%.1,63 Pregnant women with 
malaria in low transmission areas are often symptomatic as they have not developed 
the partial immunity to malaria, and thus suffer from fever, abdominal pain, headache, 
vomiting, and nausea.59,67 These pregnant women are also at higher risk of developing 




distress, preterm birth, stillbirth, and low birth weight frequently occur among women 
infected with malaria in pregnancy who also live in areas of low transmission.26,59,69,74  
The relationship between malaria morbidity and level of transmission is of 
increasing importance as malaria transmission decreases globally.46 However, even 
though malaria in pregnancy appears to have different health implications depending on 
the level of malaria transmission in the community, the overall disease burden could be 
similarly heavy without preventive measures including those targeted towards women 
with the highest risk of malaria in pregnancy.13 
Impact of immunity on malaria in pregnancy 
All parity groups have an increased susceptibility to malaria infection in 
pregnancy.13,67 However, over successive pregnancies, women naturally acquire 
resistance to malaria in pregnancy.13 P. falciparum-infected erythrocytes bind to the 
syncytiotrophoblast, and this sequestration in the placenta is mediated by VAR2CSA.12 
P. falciparum-infected erythrocytes avoid splenic clearance by binding to CSA in the 
placenta.13 Over successive pregnancies, antibodies to VAR2CSA are developed and 
thus inhibit binding of P. falciparum-infected erythrocytes to the placenta.12 This parity-
dependent malaria immunity is associated with reduced parasite density, decreased 
clinical disease, and reductions in placental and peripheral parasitemia.13 
Therefore, women without this acquired parity protection are at greatest risk to 
malaria in pregnancy and consequent negative health outcomes.13 Primigravidae 
women have not yet acquired this pregnancy-specific immunity of antibodies against 
VAR2CSA, and consequently cannot prevent infected erythrocytes from binding to CSA 




placental infection which is associated with low birth weight and maternal anemia.13–17 
The increased prevalence and parasite density of P. falciparum among primigravidae 
during pregnancy is found at all levels of malaria transmission.44 
In areas of low transmission, the difference in parity-dependent susceptibility is 
less marked although primigravidae still have a higher parasite prevalence.59 In high 
malaria transmission areas, the acquired immunity from stable exposure to P. 
falciparum parasites frequently leads to asymptomatic malaria even though the placenta 
may be heavily infected leading to consequent negative birth outcomes.66,67 This parity-
dependent susceptibility places primigravidae women at greatest risk to high parasite 
density and negative health outcomes.13  
The prevalence of malaria in primigravidae may be high because of infected 
women becoming pregnant, rather than pregnant women becoming infected.21 These 
long-duration infections acquired pre-conception may be frequent as ITN use is low 
among young women.21,75,76 Many women obtain ITNs through ANC visits, and thus are 
not protected in their first pregnancy before their ANC visit.21 If these ITNs are retained 
and used, women in subsequent pregnancies will be more protected from malaria 
infection in pregnancy and subsequent health outcomes.21 However, this distribution of 
ITNs at ANC leaves primigravidae women, who are already at higher risk of malaria 
infection because of parity-dependent immunity, unprotected until their first ANC.21 
Potential biological mechanisms of malaria in the first trimester 
Pregnant women are at increased susceptibility to malaria partially due to 
immune system changes in order to accept the fetal allograft, and partially due to the P. 




Sequestration of malaria in the placenta and consequent increase in the risk of low birth 
weight has been established.1 Low birth weight caused by malaria is likely through 
intrauterine growth restriction and preterm delivery.77 Parasite sequestration can cause 
placental insufficiency, leading to decreased nutrient transport that likely leads to 
intrauterine growth restriction.55 Preterm delivery also contributes to low birth weight and 
has been associated with malaria infection near delivery.1 
Malaria infection in the first trimester could impact placental development and 
thus affect fetal growth.55,68,78 Placental circulation development occurs during the first 
trimester, peaking between 10 to 12 weeks of gestation.79 In addition, P. falciparum 
parasitemia is highest between 13 to 18 weeks of gestation.66 As the peak prevalence 
of malaria in pregnancy is in late first trimester and early second trimester, the 
susceptibility to malaria must increase in the first trimester.1 Changes in splenic function 
caused by pregnancy can increase the risk of P. falciparum infection in primigravidae as 
early as 8 weeks of gestation.1,80 
While the impact of malaria during embryogenesis (which occurs between 6 to 13 
weeks of gestation) when erythroblasts are the primary form of circulating red blood 
cells is not fully understood, current evidence suggests that negative birth outcomes are 
correlated with placental sequestration of erythrocytes and that malaria infection alters 
placental vascular development.7,54,62,63,69 
P. falciparum-infected red blood cells bind to the syncytiotrophoblast in the 
placenta, a process mediated by VAR2CSA.12 This sequestration of malaria parasites is 
associated with fetal growth restriction.10 However, sequestration has been suggested 




formation of the placenta which occurs approximately at the 14th week of gestation.78 
The fetus develops in a hypoxic medium prior to the vascularization of the intervillous 
spaces around the 12th week of gestation.62 Therefore, infected erythrocytes from 
maternal blood should not have access to the intervillous spaces of the placenta and 
thus theoretically be unable to adhere to CSA expressed in these spaces.62 Thus, the 
infections occurring in early pregnancy were suggested to only induce negative birth 
outcomes by occurring after (or persisting until after) the placenta is formed, and then 
cytoadhering to the placenta.78 However, Doritchamou et al. found that P. falciparum 
parasites isolated as early as 7 weeks of gestation transcribed VAR2CSA and exhibited 
CSA-adhering phenotypes, thus suggesting the possibility of sequestration this early in 
pregnancy.62 Our understanding of placental vascularization may be incomplete, as 
intervillous blood flow has been reported from the 6th week of gestation and thus 
placental irrigation may develop earlier than previously concluded.62 In addition, the 
trophoblasts from the fetus that invade maternal uterine arteries may express CSA, thus 
potentially providing infected erythrocytes an initial location for sequestration during the 
first trimester.62 Therefore, women in the first trimester may be infected with malaria 
parasites that express VAR2CSA, and thus could potentially have sequestered 
pregnancy-associated parasites leading to negative birth outcomes.62 
Alternatively, malaria infection in the first trimester could impact the placentation 
process and thus impact fetal growth.55,68,78 During this time, the trophoblast invades 
and remodels the maternal uterine arteries in order to increase uterine artery blood 
flow.48 Trophoblast invasion is essential for normal placental function and fetal growth, 




placentation is particularly sensitive to pathology in the first trimester, and malaria in 
early pregnancy can inhibit trophoblast invasion.9,10 Disruptions can impair placental 
function by reducing utero-placental blood flow contributing to the pathogenesis of low 
birth weight and intrauterine growth restriction.9,10,48 
Research has suggested that malaria in early pregnancy may lead to disruptions 
in placentation. For instance, plasma collected from pregnant women infected with P. 
falciparum malaria between 16 and 22 weeks of gestational age was shown to inhibit 
trophoblast migration but not trophoblast viability.81 A small study of 4 pregnant women 
found that malaria infection before 24 weeks of gestation is associated with smaller 
placental volume which is linked to impaired trophoblast invasion.82 Griffin et al. found 
that malaria infections occurring prior to 20 weeks of gestation affects uterine and 
umbilical artery blood flow.48 Among primigravidae, malaria infection prior to 20 weeks 
of gestation decreased umbilical artery resistance in the third trimester, suggesting 
adaptive villous angiogenesis and increased risk of intrauterine growth restriction.48 In 
contrast, McGready et al. found that malaria detected and treated early in pregnancy in 
an area of low transmission rarely leads to placental changes indicating potential 
placental recovery.10,83 However, these studies all used wide intervals to define early 
pregnancy. 
Using a narrow interval, Moeller et al. found that malaria in the first trimester (i.e., 
before 15 weeks of gestation) was associated with negative impacts on placental 
vascular development and consequent pregnancy outcomes.11,12 However, this 
relatively small study of 68 women had recruited mostly multigravidae in an area of 




would be even more pronounced among primigravidae or nulliparous women, and 
among women living in high malaria transmission areas.11 
Although the first trimester might represent a critical time for intervention to 
prevent the negative consequences of malaria in pregnancy, few studies have assessed 
malaria in the first trimester because most studies are limited to observations in the 
second trimester when women begin receiving ANC.23,77 In addition, studies of pregnant 
women in the first trimester are faced with serious challenges including time-consuming 
and expensive longitudinal follow-up and difficulties obtaining accurate measurement of 
gestational age.23,77 
Previous research on malaria in early pregnancy 
Research of low P. falciparum transmission settings and impact on early 
pregnancy are restricted to a few studies. In 1989 to 1990, a case-control and 
community cohort study examined the association of malaria infection and low birth 
weight in Sudan in an area of low to moderate transmission, and found that the risk of 
low birth weight was highest if the malaria infection occurred in the first trimester.84 In 
addition, women in their first pregnancy had a high risk of low birth weight.84 This study 
relied on retrospective malaria history during pregnancy given by the mother at delivery, 
potentially leading to differential recall bias and misclassification.39,84  
Most research on low malaria transmission settings in early pregnancy is based 
at the Shoklo Malaria Research Unit located at the Thai-Burmese border.10,52,54,82,85 This 
southeastern Asian cohort with both P. falciparum and P. vivax malaria transmission 
began in 1986 and has collected data for over 30 years.10,52,54,82,85 Although exposure to 




used to measure gestation age, and quality of ANC could have affected their results, 
they found that a single episode of P. falciparum malaria in the first trimester (< 14 
weeks of gestation) was associated with miscarriage, especially among those with two 
or more infections in the first trimester.52,54,85 However, a successfully treated episode of 
P. falciparum malaria in the first trimester was not associated with low birth weight, 
suggesting either minimal impact of the malaria infection in the first trimester on birth 
weight or placental recovery in utero.85 The rates of P. falciparum malaria were highest 
at 6 weeks of gestation and declined as the pregnancy progressed, and symptomatic or 
asymptomatic P. falciparum malaria detected and treated after 12 weeks of pregnancy 
was associated with increased risk of small for gestational age, but they found no 
association if the malaria infection was detected and treated between 4 to 12 weeks of 
gestation.10 However, this southeastern Asian cohort with low transmission of both P. 
falciparum and P. vivax may not be representative of the malaria burden of women in 
sub-Saharan Africa where P. falciparum substantially predominates or in areas of high 
transmission.52 
Several more studies have focused on malaria infection in early pregnancy in 
higher P. falciparum transmission settings in sub-Saharan Africa. Cottrell et al. 
conducted a retrospective analysis of pregnant women from an area with high malaria 
transmission burden in Burkina Faso from 1987-88 and found a decreasing trend in the 
mean birth weight when peripheral malaria infection was detected before 4 months of 
gestation.39 Griffin et al. studied the impact of early malaria infection on fetal growth and 
uterine growth in a small ultrasound study of 128 pregnant women from the DRC from 




with intrauterine growth restriction among primigravidae, and decreased uterine and 
umbilical artery blood flow in the late third trimester.48 Valea et al. studied pregnant 
women in Burkina Faso from 2006-08, and found that the 31 women studied who were 
infected with malaria during the first trimester had higher risk of delivering a low birth 
weight baby compared to women who were never infected with malaria during 
pregnancy.86 In contrast, De Beaudrap et al. found no association between a single 
detected and treated infection before 20 weeks of gestation and low birth weight.6,47 
However, this study of pregnant Ugandan women conducted between 2006-09 had only 
12 women infected with malaria prior to 15 weeks of gestation out of the total 120 
pregnant women recruited by that time of gestation, and therefore the impact of malaria 
in the first trimester could not be accurately assessed.6,47 Kalilani-Phiri et al. determined 
that among a cohort of Malawian pregnant women studied between 2009-10, infections 
that occurred in early pregnancy prior to or at the onset of the first ANC visit was 
associated with placental infection, but discarded the 36 pregnant women recruited in 
the first trimester from their analysis because of small numbers.87 
Ancillary studies on the STOPPAM (Strategies to Prevent Pregnancy-Associated 
Malaria) prospective cohort conducted in Tanzania and Benin in 2008-11 found that 
Tanzanian pregnant women infected within the first 4 months of pregnancy had 
restricted fetal growth among primigravidae, restricted intrauterine growth in the third 
trimester, reduced birth weight, and reduced placental weight.9,88 When restricting their 
study population to women recruited before gestational day 97 (i.e., first trimester), their 
analysis of 14 exposed and 46 non-exposed women found a non-significant reduction in 




Briand et al. used the same study design (as Schmiegelow et al. did in Tanzania), and 
found that infections in early pregnancy were associated with reduction in fetal growth 
velocity.9,89 Also in Benin, Huynh et al. found that malaria infection prior to the fifth 
month of gestation was associated with decreased mean birth weight and increased 
maternal anemia.78 Finally, Cottrell et al. found that submicroscopic infections early in 
pregnancy among Beninese women (i.e., at inclusion - mean gestational age 16.5 
weeks, standard deviation 4.8 weeks) were associated with an increased risk of low 
birth weight among primigravidae.4 
Elphinstone et al. found that among a cohort of Malawian women enrolled 
between 2011-13, malaria infection detected before 24 weeks of gestation was 
associated with an increased risk of preterm birth.7 However, they only enrolled women 
were had at least 13 weeks of gestation, and therefore their analysis did not include 
most of the first trimester of pregnancy.7 Moeller et al. examined 28 placentas infected 
before 15 weeks of gestation, and found that malaria before 15 weeks of gestation 
negatively impacted placental vascular development.11 
In addition, other studies have examined malaria in early pregnancy but have not 
focused on birth outcomes. Berry et al. determined risk factors of malaria in early 
pregnancy in areas with seasonal malaria transmission by using data from a 
randomized control trial conducted in Burkina Faso, The Gambia, Ghana and Mali.21 
They found that risk factors of malaria infection at the first ANC visit (between 16 and 30 
weeks of gestation) include the duration of pregnancy spent in the rainy season, age, 
gravity, and socioeconomic status, but did not find an effect of bed net use on malaria 




20 weeks of gestation, they did not examine the relationship between malaria in early 
pregnancy and adverse birth outcomes but instead examined the burden of malaria 
during pregnancy (i.e., number of infections during pregnancy) and adverse birth 
outcomes.90 
The above studies’ limitations include data collection occurring decades ago, 
small numbers of pregnant women in early pregnancy examined, large early pregnancy 
intervals (e.g., first half of pregnancy, less than 20 weeks of gestation), and imprecise 
measurements of gestational age. In order to address these limitations, the RECIPAL 
(REtard de Croissance Intra-uterine et PALudisme) preconceptional cohort was 
developed to assess the effects of malaria during the first trimester of pregnancy.22,23,91–
93 Briefly, from 2014-17, 1,214 Beninese women of reproductive age were recruited and 
followed until 411 became pregnant.22,23,91–93 These 411 pregnant women were followed 
from 5-6 weeks of gestation (as determined by ultrasound) until delivery of which 273 
women delivered with complete follow-up.22,23,91–93 
These researchers found that the proportion infected with malaria (both 
microscopic and submicroscopic) was highest in the first trimester and that malaria 
infection in the first trimester was associated with an increased risk of maternal anemia 
in the third trimester, but was not associated with an increased risk for negative birth 
outcomes including preterm birth, small for gestational age, or low birth weight.23,92 In 
addition, ITN use in the first trimester reduced the risk of malaria infection, and women 
infected before conception were more likely to be infected in the first trimester.22,91,93 
While the RECIPAL study has many strengths including screening of women very early 




included only 24 births with complete follow-up from primigravidae even though 
primigravidae are the most likely to have negative birth outcomes due to malaria 
infection.92 Therefore, the prevalence of negative birth outcomes was likely 
underestimated by the underrepresentation of primigravidae in the final RECIPAL 
cohort.91 
These studies suggest that malaria in early pregnancy, when current 
recommended strategies either cannot or are rarely used, is a critical under-protected 
period in pregnancy that potentially because of placental recovery is associated with 
some but not all poor health outcomes. However, these previous studies are limited by 
occurring decades prior, defining wide intervals for early pregnancy, using imprecise 
measurements of gestational age, examining only a single-site, and including small 
numbers of pregnant women and even fewer primigravidae women (who have the 
highest risk of malaria in pregnancy and are the least protected). In order to expand 
understanding of malaria in the first trimester, we have analyzed a large cohort of 
nulliparous women between 6-14 weeks of gestation (as determined by ultrasound) to 
characterize the predictors of malaria in the first trimester and estimate its effects on 
maternal and birth outcomes. 
Predictors of malaria in pregnancy overall and in early pregnancy 
Predictors assessed in this dissertation include maternal age, maternal height, 
maternal body-mass index (BMI), maternal education, seasonality, and socioeconomic 
status. We have summarized and compared the previous research on predictors of 
malaria in pregnancy overall or of malaria in early pregnancy in Table 2.2. The few 




results on maternal age, socioeconomic status, and seasonality.21,22,88 In addition, only 
one study examined maternal height, maternal BMI, or maternal education as a 
predictor of malaria in early pregnancy.88 In contrast with the well-studied predictors of 
malaria in pregnancy, younger age was not conclusively associated with higher 
prevalence of malaria in early pregnancy.7,20–23,43,57,94–101 In addition, while short stature 
in Malawi,98 low BMI in Kenya,99 and lower overall educational attainment in multiple 
countries6,7,100–103 were associated with malaria in pregnancy overall, a single study did 
not find an association between maternal height, maternal BMI, and maternal education 
and malaria in early pregnancy.88 We have addressed this clear gap in the knowledge 
base by characterizing predictors of malaria in the first trimester in a large multi-site 
study of nulliparous women.  
Maternal and birth outcomes of malaria in pregnancy overall and in early pregnancy 
Birth outcomes assessed in this dissertation include low birth weight, preterm 
birth, small for gestational age, and perinatal mortality. Malaria in pregnancy is 
associated with an increased risk of low birth weight, and in malaria-endemic areas, 
about one-fifth of cases of low birth weight is attributable to placental malaria infection.25 
Malaria in pregnancy causes low birth weight through preterm delivery and through 
intrauterine growth restriction.25 Preterm delivery due to malaria infection may be 
caused by the response of the immune system prompting early delivery.25 Intrauterine 
growth restriction due to malaria infection may be caused by decreased nutrient delivery 
to the fetus, leading to term small for gestational age birth.25 
Maternal outcomes assessed in this dissertation include maternal anemia in late 




associated with an increased risk of maternal anemia, with about one-fourth of severe 
anemia in pregnancy attributable to malaria infection.25 Anemia in pregnancy due to 
malaria infection is caused by hemolysis, reduced red blood cell production, and 
increased splenic removal of red blood cells.25 Hypertensive disorders in pregnancy 
including preeclampsia and gestational hypertension have been suggested to be 
associated with malaria in pregnancy by malaria parasites causing a dysfunctional 
placenta leading to hypertensive disorders.104 
We have summarized the literature on the effect of malaria in pregnancy overall 
or of malaria in early pregnancy on maternal and birth outcomes in Table 2.3. The few 
studies have found conflicting results on the effect of malaria on preterm birth, maternal 
anemia, and low birth weight.4,6,7,11,20,39,84–86,88,92 Three studies found no association 
between malaria in early pregnancy and small for gestational age,7,10,92 and no studies 
have published on the effect of malaria in early pregnancy on hypertensive disorders or 
perinatal mortality. While malaria in pregnancy overall is associated with adverse 
outcomes including preterm birth, anemia in late pregnancy/at delivery, small for 
gestational age, and low birth weight, the few studies on malaria in early pregnancy 
show conflicting results. Therefore, we were able to address this need for further 
research by estimating the causal effect of malaria in the first trimester on maternal 
outcomes including anemia in late pregnancy and hypertensive disorders, and birth 





Table 2.2. Comparison of reported relationships of predictors to either malaria in 
pregnancy overall or malaria in early pregnancy 
  
Predictor 
Reported relationship(s) to: 











(younger vs. older) 
7,43,57,94,95,97–
101,105 
106,107 21 22,88 
Maternal height 














(lower vs. higher) 





95,98,106 53 21 22 
Socioeconomic 
status (SES) 
(lower vs. higher) 




Table 2.3: Comparison of reported relationships of either malaria in pregnancy 
overall or malaria in early pregnancy and maternal or birth outcome 
Outcome Reported relationship(s) to: 
 Malaria in pregnancy (overall) Malaria in early pregnancy 
 
Higher risk of 
outcome 
No association 
Higher risk of 
outcome 
No association 

















Anemia in late 
pregnancy/at 
delivery 
















CHAPTER III: METHODS 
Chapter 3  
Study Site 
The Eunice Kennedy Shriver NICHD Global Network for Women’s and Children’s 
Health Research was developed to conduct clinical trials in resource-limited countries to 
evaluate low-cost sustainable interventions aimed at improving health of women and 
children.130 Since 2013, the NICHD Global Network has conducted research in multiple 
low and middle income countries, including three countries in sub-Saharan Africa: 
Democratic Republic of the Congo (DRC), Kenya, and Zambia.130  
This malaria sub-study was nested within the NICHD Global Network’s trial of 
low-dose aspirin for the prevention of preterm delivery in nulliparous women with a 
singleton pregnancy.18,19 This Aspirin Supplementation for Pregnancy Indicated Risk 
reduction In Nulliparas (ASPIRIN) trial was a prospective, randomized, multi-national 
clinical trial that tested the hypothesis that low-dose acetylsalicylic acid initiated in the 
first trimester reduces the risk of preterm birth.19 The trial recruited 11,920 nulliparous 
women between March 23, 2016 and April 11, 2019 at seven research sites in six 
countries (DRC, Zambia, Guatemala, Pakistan, Kenya, and two sites in India), who 
were randomly assigned 1:1 to receive either daily low-dose acetylsalicylic acid (81 mg 
dose) or a visually identical placebo, beginning in the first trimester (gestational age 
between 6 weeks, 0 days and 13 weeks, 6 days, confirmed by study ultrasound) and 




individually randomized by site and the randomization sequence was developed using a 
randomly permuted block design with varying block sizes.19 
 In the DRC, the Global Network sites are in the Northwest provinces of Nord and 
Sud Ubangi, and the site coordinating center is in Kinshasa.130 There are 14 clusters 
which are each served by a health center where care is administered by nurses.130 
Physicians, nurse midwives, and nurses run the three hospitals; there are no specialty 
physicians available.130  
In Kenya, the Global Network sites are in western Kenya in the counties of Busia, 
Bungoma, and Kakamega, and the site coordinating center is in Eldoret.130 There are 16 
clusters which are served by 23 health facilities where care is administered by nurse-
midwives, clinical officers, and a single medical officer.130 The three hospitals act as 
referral hospitals and are run mostly by generalist physicians, with a few trained 
obstetricians and pediatricians.130  
In Zambia, the Global Network sites are in southern Zambia in the districts of 
Kafue and Chongwe, and the site coordinating center is in Lusaka.130 There are 10 
clusters, of which 8 have health posts where care is administered by nurse midwifes.130 
Traditional birth attendants provide care for home births.130 In Lusaka, there are three 
district hospitals and a referral hospital, but specialty physicians are only available at the 
referral hospital.130 
This malaria in the first trimester sub-study was conducted among 1,513 women 
in the ASPIRIN trial from the sub-Saharan African sites (485 women from DRC, 677 




from primary health-care centers and hospital-based clinics, and each site screened 
pregnant women residing within the community for eligibility in the ASPIRIN trial.19  
 
 
Figure 3.1: Map of NICHD Global Network sub-Saharan African sites 
In the DRC, the research sites are in Nord and Sud Ubangi (shaded in light orange), 
and the site coordinating center is located in Kinshasa (the capital, noted by orange 
dot). In Kenya, the research sites are in the counties of Busia, Bungoma, and 
Kakamega (shaded in light orange), and the site coordinating center is located in 
Eldoret (noted by orange dot). In Zambia, the research sites are within the districts of 
Kafue and Chongwe (shaded in light orange), and the site coordinating center is located 
in Lusaka (the capital, noted by orange dot). Figure modified from Bose et al., 2015.130 
 
Study Population 
The ASPIRIN trial targeted nulliparous women who were in their first trimester of 









from six countries by using clinic-based and community-based recruitment strategies as 
determined by each study site in order to reach a diverse study population.18,19 Women 
were asked if they were nulliparous and pregnant between 6 weeks 0 days and 13 
weeks 6 days based on last menstrual period.18 Ultrasound was used to determine 
gestational age after enrollment.18 The source population for this sub-study were all 
pregnant women who participated in the ASPIRIN trial who lived in countries with 
endemic malaria (i.e., DRC, Kenya, and Zambia). The sampling population for this sub-
study were pregnant women from DRC, Kenya, and Zambia who enrolled in the 
ASPIRIN trial and had dried blood spots (DBS) obtained at enrollment that were tested 
for malaria parasites and classified as positive or negative for malaria parasites.  
The inclusion criteria from the ASPIRIN trial included nulliparous women between 
18-40 years of age (possibility of minors who are 14 or older being enrolled if allowed by 
the country’s guidelines) who are residents of the study area, who had no more than 
two previous first-trimester pregnancy losses and no medical contraindications to 
acetylsalicylic acid.18,19 In addition, all women at enrollment must have had a single live 
intrauterine pregnancy that was between 6 weeks and 0 days to 13 weeks and 6 days in 
gestational age that was confirmed by an early dating ultrasound and the presence of a 
heartbeat.18,19 
Exclusion criteria for the ASPIRIN trial included women who were already 
prescribed daily acetylsalicylic acid for more than a week, and women with multiple 
gestations.18,19 Further exclusion criteria included a fetal anomaly detected by 
ultrasound at screening, women with severe anemia (hemoglobin levels < 7.0 g/dL at 




and diastolic  90 mm Hg at screening), or any women with any medical condition that 
may be a contradiction to receiving acetylsalicylic acid, as evaluated by the site 
investigator (e.g., Type 1 diabetes, lupus, hypertension, or other significant 
disease).18,19 
The inclusion criteria for the first aim assessing predictors of malaria in the first 
trimester included all randomized participants from the DRC, Kenya, and Zambia who 
had a DBS collected in the first trimester and a quantitative PCR (qPCR) malaria result 
of positive or negative (n=1513). For the second aim estimating effects on maternal and 
birth outcomes, participants additionally had to provide any post-baseline outcome data 
and have delivered at 20 weeks of gestational age or greater (n=1446).  
Participant Data and Sample Collection 
At enrollment, information was collected on demographics (including years of 
maternal age and education), pregnancy and medical history, and current medical 
information (including height in centimeters, weight in kilograms, blood pressure, heart 
rate, and history of diabetes).19 Dried blood spots (DBS) were also collected by pricking 
the participant’s finger and placing three blood spots on filter paper, which were then 
completely dried before storage at room temperature in plastic bags with desiccant. 
DBS were also collected in late pregnancy between 26-30 weeks of gestation. DBS 
were collected from all eligible women who consented to this sub-study who were 
enrolled between January 2016 to April 2018. 
Maternal outcomes included vaginal bleeding, antepartum hemorrhage, 
postpartum hemorrhage, maternal mortality, late pregnancy termination, change in 




included preterm birth, low birth weight, fetal loss, spontaneous abortion, stillbirth, small 
for gestational age newborn, perinatal mortality, and medical termination of 
pregnancy.19 Maternal and birth outcomes were obtained up to 42 days following 
delivery using the Global Network Maternal and Newborn Health Registry.19 
Sample Processing 
Participant DBS samples were shipped to the Meshnick lab at the University of 
North Carolina at Chapel Hill in Chapel Hill, North Carolina where they were processed 
to detect P. falciparum. DBS were retrospectively tested in duplicate for P. falciparum 
lactate dehydrogenase (pfldh) nucleic acid using qPCR, a sensitive molecular detection 
method.131 DBS were distributed into a 96-well plate with one punched DBS per 
participant per well. P. falciparum parasite nucleic acid was extracted from each sample 
using Chelex. Each sample was tested in duplicate for pfldh nucleic acid using qPCR; 
human ß-tubulin was used as a nucleic acid control. Samples were defined as positive 
for P. falciparum infection when florescence for both replicates crossed the threshold 
prior to the 39th cycle, or when one replicate did not amplify and the other crossed the 
threshold prior to the 39th cycle. Discordant results between duplicates were excluded 
from analysis. A convenience sample of DBS was included in this analysis. 
Defining the analytic data set 
Of the 3,628 dried blood spots analyzed by qPCR, 3,497 were successfully 
merged with the ASPIRIN dataset, had a non-missing expected delivery date, and had a 
non-missing collection date. The difference between the expected delivery date and the 
collection date was determined and subtracted from 280 days (i.e., 40 weeks) to obtain 




age at sample collection in days was then divided by 7, and then rounded to the floor to 
obtain the estimated gestational age at sample collection in weeks (i.e., 6 weeks 6 days 
became 6 weeks). The first trimester was defined as having an estimated gestational 
age between 6 weeks 0 days and 13 weeks 6 days inclusive at the time of collection.  
In order to ensure that only one sample from each woman would be defined as 
obtained in the first trimester, the de-duplication process varied depending on 
gestational age at each sample collection and the qPCR result of the sample. If multiple 
samples from the same woman were defined as obtained in the first trimester and had 
different gestational age in weeks at sample collection, the sample collected at the 
earlier gestational age was included. De-duplicating samples was based solely on which 
sample had the earlier gestational age at collection in weeks as the qPCR result of 
positive or negative for P. falciparum was not examined. If multiple samples from the 
same woman were defined as obtained in the first trimester and had the same 
gestational age in weeks at sample collection, de-duplication then depended on the 
qPCR result for P. falciparum. If the results were concordant, then one sample was 
randomly labeled as a duplicate. If one result was positive or negative and the result 
was not available (i.e., not positive or negative), the sample with a positive or negative 
result was included and the sample with a not available result was excluded. Finally, if 
results were discordant, all samples were labeled as discordant and excluded from 
further analysis. After de-duplication, any sample that was included but not randomized 
in the ASPIRIN trial was excluded.  
Thus, only non-duplicated randomized samples classified as obtained in the first 




P. falciparum infection were included. Thus, analysis on predictors of malaria in the first 
trimester is based on 1,513 samples each collected from a nulliparous woman in the 
first trimester of pregnancy from DRC, Kenya, and Zambia. As participants additionally 
had to provide any post-baseline outcome data and have delivered at 20 weeks of 
gestational age or greater to be included in the study population for Aim 2, analysis of 
the effect of malaria in the first trimester on maternal and birth outcomes is based on 
1,446 samples each collected from a nulliparous woman in the first trimester from DRC, 
Kenya, and Zambia.  
Innovation and comparison to previous studies 
To clarify what increases the likelihood of malaria in the first trimester, and to 
estimate the causal effects of malaria in the first trimester on adverse maternal and birth 
outcomes, we used a stronger study design and improved methodology compared to 
previous work. We analyzed malaria in the first trimester among a large population of 
pregnant women from multiple sites compared to previous studies that were small and 
single-site. By including multiple sites, we were able to study how malaria morbidity 
changes in different transmission settings, which is of increasing importance as malaria 
transmission decreases globally.46,125 
The women we studied were predominantly women with the highest risk of 
malaria in pregnancy and consequent negative health outcomes, i.e., women in their 
first pregnancy (primigravidae), compared to other studies that have mostly included 
multigravidae instead of primigravidae women.13,44 Because they lack parity-dependent 
immunity that reduces placental and peripheral parasitemia, primigravidae women have 




Primigravidae have higher prevalence and parasite density of P. falciparum in 
pregnancy than women with higher parities.44 As many pregnant women acquire ITNs 
through their first antenatal care visit, and women rarely use ITNs before and during 
their first pregnancy, this habitually leaves women in their first trimester of their first 
pregnancy unprotected from malaria infection.8,21,23 While we studied nulliparous 
women, most women in our study were primigravidae, and thus our sub-study was able 
to address an important gap in knowledge about malaria in pregnancy among the most 
affected group. 
We restricted our definition of early pregnancy to the first trimester (i.e., 6-<14 
weeks of gestation) compared to previous studies that defined early pregnancy as wide 
as the first half of pregnancy. We used ultrasounds to accurately measure gestational 
age in the first trimester. Little is known about the biological mechanism of malaria in the 
first trimester. As the placenta forms about 14 weeks of gestation, whether 
sequestration of P. falciparum parasites in the placenta can occur in the first trimester is 
of some debate.62,78 In addition, malaria infection before 15 weeks of gestation was 
associated with negative placental vascular development.11 Therefore, by restricting 
malaria to the first trimester, we were able to estimate causal effects of malaria in the 
first trimester on adverse maternal and birth outcomes. 
We used PCR, a very sensitive molecular detection method of malaria infection 
during pregnancy, compared to other studies that used placental histology, microscopy, 
or RDTs, that allows us to detect low-density infections common in pregnancy including 
subpatent and submicroscopic infections. The only way to detect malaria infection 




parasitemia in pregnancy is often very low and undetectable by most standard methods, 
diagnosing malaria in pregnancy is difficult.36,37 PCR is a very sensitive method to 
detect malaria infection in peripheral blood and can detect subpatent and 
submicroscopic infections.37,40,48–50 By using a very sensitive method of detection of 
malaria infection, we were able to detect and analyze even low-level malaria infections 
in the first trimester. 
We leveraged a past multi-national clinical trial that specifically recruited women 
in the first trimester (i.e., 6 weeks 0 days to 13 weeks 6 days of gestation) in order to 
decrease costs and increase efficiency while developing the first large multi-site study of 
malaria in the first trimester. Additional data collected for this sub-study were minimal 
(DBS at enrollment and at late pregnancy), and as low-dose aspirin was randomly 
assigned, we did not need to control for the effects of the ASPIRIN study protocol. From 
this DBS, we were able to determine P. falciparum infection at the first trimester of 
pregnancy including low-density infections that cannot be detected by RDT or 
microscopy, and then we linked these malaria test results to the extensive amount of 
already collected information. We thus were able to determine crucial information about 
predictors and consequent maternal and birth outcomes of malaria in the first trimester 
by leveraging an existing clinical trial.  
In this first large multi-site study on malaria in the first trimester, we were able to 
characterize predictors of malaria in the first trimester and estimate the causal effect of 
malaria in the first trimester on adverse maternal and birth outcomes.  
Data analysis  




literature. As only two studies have assessed predictors of malaria in the first 
trimester,22,88 we assessed six predictors to characterize the factors which are 
associated with increased likelihood of malaria in the first trimester. Likewise, limited 
research has assessed the impact of malaria in the first trimester on maternal and birth 
outcomes. The overall objective of this dissertation was to characterize predictors of 
malaria in the first trimester, and to estimate causal effects of malaria in the first 
trimester on adverse maternal and birth outcomes. All comparisons were limited to 
observations without missing data for each variable, and models were limited to 
observations without missing data for all covariates and the outcome. All analyses were 
conducted using R version 4.0.2.126 
Aim 1 Predictor, Variable, and Outcome Assessment 
The first specific aim was to characterize the factors which are associated with 
increased likelihood of malaria in the first trimester.  
The main outcome was malaria in the first trimester, defined as a positive result 
for P. falciparum through qPCR in a sample obtained at enrollment. 
 Based on previous studies of malaria infection in late pregnancy, we examined 
the following predictors: maternal age, maternal height, maternal body-mass index 
(BMI), maternal education, season coincident with the first trimester, and socioeconomic 
status.  
Maternal age was measured in years at enrollment. Maternal height was 
measured in centimeters at enrollment. Maternal BMI was calculated from the maternal 
weight recorded at enrollment in kilograms divided by the maternal height recorded at 




formal schooling, primary education (1-6 years of schooling), secondary education (7-12 
years of schooling), or university and beyond education (≥13 years of schooling). 
Season coincident with the first trimester of pregnancy was defined as rainy or not-rainy 
based on the month of the date of collection recorded on the malaria DBS filter paper 
sample with the specific months defined as rainy varying across countries: April to 
October in DRC,133 April to June and October to November In Kenya,134 and November 
to April in Zambia.135  
To calculate socioeconomic status (SES), we used the Global Network 
Socioeconomic Status Index.136 Developed from around 50,000 households of pregnant 
women included in GN, the Socioeconomic Status Index is calculated by determining 
the number of 10 specific items owned by the household to develop a country-specific 
score.136 The specific items were dichotomized as yes or no. The sum score for Kenya 
or Zambia is the number of the following items that were owned by the household: 
improved source of drinking water, flush toilet, finished floor material, motorbike, car, 
smartphone, television, electricity, refrigerator, and use of liquid petroleum gas or 
electricity as cooking fuel.136 Because few households in the DRC had a refrigerator or 
used liquid petroleum gas or electricity for cooking fuel, the SES Index instead uses two 
additional lower SES items for DRC: more than one room in home and bicycle.136 Thus, 
the sum score for the DRC is the number of following items that were owned by the 
household: more than one room in home, bicycle, improved source of drinking water, 
flush toilet, finished floor material, motorbike, car, smartphone, television, and 
electricity.136 From the sum score of the number of items owned, it was converted to an 




Data on all predictors except season coincident with first trimester drew on the 
extant ASPIRIN study data which was reported by each of the sites to the Global 
Network Data Coordinating Center (DCC) (RTI International).18 The data were used by 
the DCC to evaluate site performance including data quality.18 To monitor data quality, a 
random 5% of the actual data collected was validated by chart review.18 DCC staff 
conducted site visits as needed to review individual participant records and ensure 
compliance with the protocol and accuracy and completeness of the records.18 
The last variable included was projected gestational age at enrollment which was 
developed from an algorithm described in Hoffman et al., 2020. Further details on the 
algorithm is presented in the Supplementary Information for Chapter IV on page 119. 
Aim 1 Analysis 
Based on previous studies of malaria infection in late pregnancy, we examined 
the following predictors: maternal age, maternal height, maternal body-mass index 
(BMI), maternal education, season coincident with the first trimester of pregnancy, and 
socioeconomic status. The ASPIRIN trial collected data required for all predictors at 
enrollment except for season coincident with the first trimester which was developed 
from the month of the collection data listed on the DBS assessed for malaria infection. 
The main outcome was malaria in the first trimester. 
For continuous variables maternal age, maternal height, maternal BMI, and 
socioeconomic status, we created two categories by dividing at the country-specific 
median based on data from this sub-study. Maternal education was dichotomized into 
two categories: lower (i.e., no formal schooling and primary education (1-6 years of 




university and beyond education (≥13 years of schooling)). Season coincident with the 
first trimester of pregnancy was defined as rainy or not-rainy. 
 Crude prevalence ratios (PRs) and prevalence differences (PDs) were calculated 
for malaria in the first trimester by each variable, using stratified 2x2 tables for each 
country. We present 99% confidence intervals to account for multiple comparisons and 
limit inflation of non-coverage rates. Our parameters of interest were the crude 
(unadjusted) prevalence ratio and prevalence difference.  
To assess heterogeneity by country, we calculated the I2 value. If I2 exceeded a 
pre-specified threshold of 40%,137 we did not pool results across countries to calculate a 
summary estimate. If the I2 value was ≤40%, we used the DerSimonian and Laird 
inverse variance method to calculate the summary estimate.137  
Aim 2 Exposure, Confounder, and Outcome Assessment 
The second specific aim was to estimate the causal effect of malaria in the first 
trimester on adverse maternal and birth outcomes. The main exposure was malaria in 
the first trimester, defined as a positive result for P. falciparum through qPCR in a 
sample obtained at enrollment.  
To estimate the causal effect of malaria in the first trimester on the assessed 
maternal or birth outcome, we identified confounders of the exposure-outcome 
relationship using causal directed acyclic graphs (DAGs) based on prior knowledge.138 
As determined by the DAGs, the minimally sufficient adjustment set to estimate the total 
effect of malaria in the first trimester on any of the assessed maternal and birth 
outcomes was maternal age, maternal education, socioeconomic status, malnutrition, 




Maternal age was measured in years at enrollment. Maternal education was 
recorded at enrollment as no formal schooling, primary education (1-6 years of 
schooling), secondary education (7-12 years of schooling), or university and beyond 
education (≥13 years of schooling). Socioeconomic status was developed using the 
Global Network Socioeconomic Status Index (detailed above as SES was a predictor for 
Aim 1).136 As a proxy for malnutrition, we used maternal body-mass index (BMI) at 
enrollment. Maternal BMI was calculated from the maternal weight recorded at 
enrollment in kilograms divided by the maternal height recorded at enrollment in meters 
squared. Season coincident with the first trimester of pregnancy was defined as rainy or 
not-rainy based on the collection date recorded on the malaria DBS filter paper sample 
with the specific months defined as rainy varying across countries: April to October in 
DRC,133 April to June and October to November In Kenya,134 and November to April in 
Zambia.135 As we were limited to data collected by the ASPIRIN trial, we did not have 
data on ITNs and did not adjust for ITN use in our causal model. 
Based on previous studies of malaria infection in late pregnancy,4,7,86 we 
examined the birth outcomes of preterm delivery, small for gestational age, low birth 
weight, and perinatal mortality and the maternal outcomes of anemia in late pregnancy 
and hypertensive disorders of pregnancy. All birth outcomes were assessed as the 
prevalence at birth. The maternal outcome of anemia in late pregnancy was assessed 
as prevalence at late pregnancy (26-30 weeks of gestation). The maternal outcome of 
hypertensive disorders was assessed as prevalence during the period from late 




The main outcome of interest, preterm birth, was defined as a stillbirth or live 
birth at or after 20 weeks and 0 days of gestation and before 37 weeks and 0 days of 
gestation.19 Birth attendants are trained to collect the data and assess outcomes as part 
of the Global Network Maternal Newborn Health Registry.130 
Secondary birth outcomes of interest included small for gestational age, low birth 
weight, and perinatal mortality. Small for gestational age was defined as any live birth 
whose birth weight was measured within 4 days of delivery and the birth weight is below 
the INTERGROWTH 10th percentile for a given gestational age and sex of the 
newborn.19 Low birth weight was defined as a measured birthweight of < 2500 g 
measured within 4 days of delivery.19 Birthweight is the first weight of the fetus or 
newborn obtained after birth, ideally measured within the first hour of life.19 Perinatal 
mortality was defined as mortality in the perinatal period beginning at 20 completed 
weeks of gestation (154 days of gestation) and ending at seven completed days after 
birth.19 Perinatal mortality included stillbirths and deaths in the first week of life.19 
Miscarriages with a gestational age of 20 weeks or greater were classified as stillbirths 
and thus included in the perinatal mortality definition19  
Secondary maternal outcomes of interest included anemia in late pregnancy and 
hypertensive disorders of pregnancy. Anemia in late pregnancy was defined as 
hemoglobin level <11 g/dL measured between 26-30 weeks of gestation, based on 
WHO cut-offs for pregnant women between 26-30 weeks of gestation.139 Hypertensive 
disorders were defined as any of the following: (1) 2 consecutive time points with ≥140 
mm Hg systolic or ≥90 mm Hg diastolic where those two timepoints occur more than 7 




for the two consecutive visits, or (2) Have evidence of hypertensive disease such as: 
any reported severe adverse event of preeclampsia or eclampsia, Maternal and 
Newborn Health registry report of hypertensive disease, preeclampsia or eclampsia, or 
reports of elevated blood pressure that meet the criteria based on the American College 
of Obstetricians and Gynecologists 2013 “Hypertension in Pregnancy” Task Force 
Report at any point after 20 weeks of gestation AND have at least one report of 
elevated blood pressure that is not followed by a normal value, in which case their 
outcome classification was decided by masked clinical experts19 
Data on all confounders included except season coincident with first trimester 
and all maternal and birth outcomes drew on the extant ASPIRIN study data which was 
reported by each of the sites to the Global Network Data Coordinating Center (DCC) 
(RTI International).18 Data quality was ensured as described above for Aim 1.18  
Additional variables included projected gestational age at enrollment, antenatal 
care visits, delivery attendant, delivery location, and delivery mode. Projected 
gestational age at enrolment as described above in Aim 1 was developed from an 
algorithm described in Hoffman et al., 2020, and further details are presented in the 
Supplementary Information for Chapter IV on page 119. Antenatal care visits were 
recorded by the MNH registry and were the number of antenatal care visits recorded on 
the perinatal form. Delivery attendant was also recorded by the MNH registry and was 
categorized into four groups: (1) physician, (2) nurse, nurse midwife, lady health worker 
or health worker, (3) traditional birth attendant, or (4) family, self or other. Delivery 
location was recorded by MNH registry as one of three options: hospital, clinic or health 




four groups: vaginal (with or without forceps/vacuum), C-section, miscarriage, or 
medical termination of birth. As Aim 2 restricted to women who provided any post-
baseline outcome data and have delivered at 20 weeks of gestational age or greater, 
there were no outcomes of miscarriages or medical termination of birth within our 
analysis population.  
Aim 2 Analysis 
The main exposure of interest was malaria in the first trimester. Based on 
previous studies of malaria infection in late pregnancy,4,7,86 we examined the birth 
outcomes of preterm delivery, small for gestational age, low birth weight, and perinatal 
mortality, and the maternal outcomes of anemia in late pregnancy and hypertensive 
disorders during pregnancy. All birth outcomes were assessed as the prevalence of the 
outcome at birth.140  
The analysis population included all randomized participants who provided any 
post-baseline outcome data and who delivered at 20 weeks of gestational age or 
greater. This restriction on the data analysis was performed in recognition that missing 
data were likely to occur because of miscarriage or medical termination of pregnancy.19 
Because of this restriction on the data analysis, we were determining prevalences of 
maternal and birth outcomes. 
Crude prevalence ratios (PRs) and prevalence differences (PDs) were calculated 
for each maternal and birth outcome by malaria in the first trimester, using stratified 2x2 
tables for each country. We present 99% confidence intervals to account for multiple 
comparisons. We did not calculate the crude prevalence ratio if there were no cases of 




To assess whether the crude results from each country were too heterogeneous 
to combine, we calculated the I2 value. If I2 exceeded a pre-specified threshold of 
40%,137 we did not pool results across countries to calculate a summary estimate. If the 
I2 value was ≤40%, we used the DerSimonian and Laird inverse variance method to 
calculate a summary estimate.137 We did not pool results of any outcome that had zero 
participants in at least one of the cells when stratified by malaria in the first trimester 
exposure and country. 
After using DAGs to identify potential confounders, we determined that the 
minimally sufficient adjustment set to estimate the total effect of malaria in the first 
trimester on any of the assessed maternal and birth outcomes was maternal age, 
maternal education, socioeconomic status, malnutrition, season coincident with the first 
trimester, and insecticide-treated nets (ITNs). As a proxy for malnutrition, we used 
maternal body-mass index (BMI) at enrollment.141 
To model the continuous covariates of maternal age, BMI, and SES, we used 
restricted cubic splines with four knots at the 5th, 35th, 65th, and 95th percentiles to 
maximized flexibility of our models. For Kenya SES, the 35th and 65th percentiles were 
identical and so we used restricted cubic splines with three knots at the 5th, 50th, and 
95th percentiles. Maternal education was categorized into two categories: lower (no 
more than primary education (1-6 years of schooling)), and higher (at least some 
secondary education (7-12 years of schooling) or university and beyond education (≥13 
years of schooling)). Season coincident with the first trimester of pregnancy was either 
rainy or non-rainy. As we were limited to data collected by the ASPIRIN trial, we did not 




Our main analytic approach was parametric g-computation.142 We estimated the 
average causal effect of malaria in the first trimester on the assessed maternal or birth 
outcome. We used parametric g-computation to determine the predicted outcomes 
given all participants had the exposure of malaria in the first trimester and the predicted 
outcomes given all participants did not have the exposure of malaria in the first 
trimester.  
We initially attempted to use linear binomial models to estimated adjusted 
prevalence difference and log-binomial to estimated adjusted prevalence ratios. 
However, our models did not converge, so we instead used logistic regression as our 
model as logistic regression always converges and provides a probability within 0 and 1. 
We first modeled the association of malaria in the first trimester and the 
assessed maternal or birth outcome. We used logistic regression and adjusting for 
confounders identified by the DAG. We estimated the parameter coefficients of the 
model, and then predicted the mean outcome given everyone was exposed and given 
everyone was unexposed. The mean outcome is the weighted average of the mean 
outcomes for the combination of values for the confounders included, i.e., the 
standardized outcome.  
Our logistic regression model provided the predicted outcomes as the predicted 
log-odds. We converted these predicted log-odds to estimated mean prevalences by 
first exponentiating the predicted log odds to obtain predicted odds, and then as 
prevalence is equal to odds divided by the denominator of odds plus 1, calculating the 
predicted prevalences from the predicted odds. We then took the mean of the predicted 




exposed to malaria in the first trimester and given everyone was unexposed. From 
these mean prevalence estimates, we calculated the adjusted prevalence ratios (aPRs) 
and adjusted prevalence differences (aPDs). We then used bootstrapping with 10,000 
repetitions to determine their corresponding 99 percentile confidence intervals by 
selecting the 50th ordered value as the lower limit and 9950th ordered value as the upper 
limit.  
We thus estimated the adjusted association of malaria in the first trimester on the 
assessed outcome. However, our goal was to estimate the causal effect of malaria in 
the first trimester on adverse maternal and birth outcomes. In order to interpret our 
results of our g-computation approach as an estimate of the average causal effect, we 
would need to assume counterfactual consistency, exchangeability, and positivity.142 
Counterfactual consistency requires that the observed outcomes among those who 
were exposed (or not) is equal to the potential outcomes that would be observed given 
they were exposed (or not).142 Exchangeability exists when the potential outcomes 
under the different exposures are independent of the observed exposures.142 This 
assumption could be met by conditional mean exchangeability (i.e., the potential 
outcomes were independent of the observed exposure given the covariates). 
Conditional mean exchangeability assumes that all confounding has been controlled in 
the model.142 The final assumption of positivity requires a non-zero probability for all 
values of exposure (i.e., malaria in the first trimester or not) conditional on the variables 
required for conditional mean exchangeability.142 These assumptions of counterfactual 
consistency, conditional mean exchangeability, and positivity must be met before we 




as an estimate of the average causal effect. 
In our model, trial arm was randomly allocated without respect to malaria in the 
first trimester status and thus we did not need to control for the effects of the ASPIRIN 
study protocol. We did not adjust for malaria in late pregnancy as it is on the causal 
pathway of malaria in the first trimester and any of the assessed outcomes. We also did 
not assess the adjusted effect of malaria in the first trimester on hypertensive disorders 
as there was not a nonzero probability of malaria infection for all values of the 
confounders that would be included in the model. As we were limited to data collected 












CHAPTER IV: PREDICTORS OF PLASMODIUM FALCIPARUM INFECTION IN THE 
FIRST TRIMESTER AMONG NULLIPAROUS WOMEN FROM THE DEMOCRATIC 
REPUBLIC OF THE CONGO, KENYA, AND ZAMBIA 
Chapter 4  
Introduction 
Malaria is a serious global health issue, with an estimated 228 million cases 
annually and 411,000 associated deaths worldwide in 2018.24 Nearly 85% of malaria 
deaths globally occurred in 21 countries, mostly in children under-5 in sub-Saharan 
Africa.2 In addition to children, pregnant women constitute a high-risk group, and in sub-
Saharan Africa, 29% of all pregnancies are exposed to malaria infection.2 Malaria 
infection in pregnancy can cause maternal anemia, preterm birth, stillbirth, and low birth 
weight.1 Despite the known perinatal complications of malaria infection in pregnancy, 
our understanding of predictors associated with malaria infection in pregnancy is limited 
to studies that evaluated malaria after 20 weeks of gestation. These studies show that 
factors associated with malaria infection in pregnancy include low gravidity, rainy 
transmission season, young age, short stature, HIV infection, maternal anemia, earlier 
trimester of pregnancy, lower body-mass index (BMI), lower education, and low 
socioeconomic status.6,7,17,31,43,57,94,95,97–103,105,106 However, data is limited about the 
predictors for malaria in the first trimester, rendering incomplete our understanding of 
the epidemiology of first-trimester Plasmodium falciparum infections. 
The first trimester represents a potential target for intervention to prevent the 




could impact the placentation process by inhibiting trophoblast invasion and disrupting 
placentation, and thus affect fetal growth.9,10,55,68,78 Adverse changes in placentation 
could be even more pronounced among primigravidae (women pregnant for the first 
time) or nulliparous women (women who have never given birth) and among women 
living in high malaria transmission areas.11 Women in their first pregnancy are 
particularly vulnerable to malaria, as women naturally acquire resistance to malaria in 
successive pregnancies by developing antibodies that inhibit binding of P. falciparum-
infected erythrocytes to the placenta in subsequent pregnancies.12,13 Thus, women who 
lack this parity-dependent immunity that reduces placental and peripheral parasitemia 
are unable to clear placental parasites quickly, leading to higher placental and 
peripheral parasitemia, and chronic placental infection, which is associated with low 
birth weight and maternal anemia.13–17 
Despite the deleterious effects of malaria in early pregnancy when placentation is 
occurring, current treatment and prevention strategies habitually leave women 
unprotected from malaria. To treat and prevent incident malaria infections in pregnancy, 
the World Health Organization recommends prompt diagnosis and treatment of malaria, 
intermittent preventive therapy in pregnancy with sulfadoxine-pyrimethamine (IPT-SP), 
and use of insecticide-treated nets (ITNs).2 However, in many malaria-endemic regions, 
diagnosing malaria in pregnancy is difficult because pregnant women frequently have 
parasite densities below the detection limit of common diagnostic tools. IPT-SP is not 
initiated until the second trimester because antenatal care (ANC) typically begins 
around 20 weeks of pregnancy, and IPT-SP is not recommended earlier in pregnancy 




settings, especially those in their first pregnancy, do not use ITNs because of 
discomfort, lack of ownership, and difficulties hanging the net.3–8 These difficulties to 
diagnosing, treating, and preventing malaria leave women under-protected from malaria 
in the first trimester. 
Many women in malaria endemic areas do not receive antenatal care (ANC) until 
the second trimester, which limits efficient observation of malaria in the first trimester.77 
Only two studies to have assessed predictors of malaria in early pregnancy.22,88 These 
studies did not find a relationship between malaria in early pregnancy and maternal age, 
maternal height, maternal body mass index, socioeconomic status, or season that 
coincided with early pregnancy and found that women with lower overall educational 
attainment (no secondary education) were more likely to have malaria in early 
pregnancy.22,88 However, one study used wide intervals to define early pregnancy (i.e., 
less than 120 days) instead of using the first trimester, and both included mostly 
multigravidae and were all single-site studies.22,88 No study has assessed malaria in the 
first trimester across multiple transmission settings. 
In this work, we leverage a large clinical trial to efficiently develop the first multi-
country study of malaria in the first trimester among nulliparous women. Our study 
objective was to determine the prevalence of malaria in the first trimester across 
multiple transmission settings and characterize the predictors that are associated with 
increased likelihood of malaria in the first trimester. Based on previous work, we 
hypothesized that lower overall educational attainment (no secondary education) would 





Study Design and Sample 
We conducted a sub study of the Eunice Kennedy Shriver NICHD Global 
Network for Women’s and Children’s Health Research’s trial of low-dose aspirin for the 
prevention of preterm delivery in nulliparous women with a singleton pregnancy (the 
ASPIRIN Trial).18,19 Briefly, the ASPIRIN trial was a prospective, randomized, multi-
national clinical trial that tested the hypothesis that low-dose acetylsalicylic acid reduces 
the risk of preterm birth when administered in the first trimester.19 The trial recruited 
11,920 nulliparous women between March 23, 2016 and April 11, 2019 at seven 
research sites in six countries (Democratic Republic of the Congo, Zambia, Guatemala, 
Pakistan, Kenya, and two sites in India),19 from primary health-care centers and 
hospital-based clinics, and were initially screened for potential eligibility, specifically if 
they were nulliparous and pregnant between 6 weeks 0 days and 13 weeks 6 days 
based on last menstrual period.18 Following enrollment, ultrasound was used to 
determine gestational age.18 
The inclusion criteria from the ASPIRIN trial included nulliparous women between 
18-40 years of age (possibility of minors who were 14 or older being enrolled if allowed 
by the country’s guidelines) who were residents of the study area, had no more than two 
previous first-trimester pregnancy losses, and no medical contraindications to 
acetylsalicylic acid.19 In addition, all women must have had a single live intrauterine 
pregnancy that was between 6 weeks and 0 days to 13 weeks and 6 days in gestational 




Women were excluded if they were already taking daily acetylsalicylic acid for 
more than a week or had a multiple gestation pregnancy.19 Women were also excluded 
if a fetal anomaly was detected by ultrasound at screening, severe maternal anemia 
was present at screening (hemoglobin < 7.0 g/dL), systolic blood pressure  140 mm Hg 
or diastolic  90 mm Hg was present at screening, or if women had any medical 
condition that could be a contradiction to receiving acetylsalicylic acid (e.g., Type 1 
diabetes, lupus, hypertension, or other significant disease), as evaluated by the site 
investigator.19 
The sub-Saharan African study sites were located in Nord-Ubangi and Sud-
Ubangi provinces in the Democratic Republic of the Congo; Bungoma, Busia, and 
Kakamega provinces in Kenya, and Kafue and Chongwe districts in Zambia (Figure 
4.1). Each site had multiple recruitment locations.  
Participant Data and Sample Collection and Processing 
At enrollment, information was collected on demographics, including years of 
maternal age and education, pregnancy and medical history, and current medical 
information, including height in centimeters, weight in kilograms, blood pressure, heart 
rate, and diabetes.19 Dried blood spots (DBS) were also collected by pricking the 
participant’s finger and placing three blood spots on filter paper, which were then 
completely dried before storage in plastic bags with desiccant. Eligible women who 
consented for the sub-study were enrolled from January 2016 to April 2018. 
DBS were shipped to the Meshnick Lab at the University of North Carolina at 
Chapel Hill in Chapel Hill, North Carolina where each was tested in duplicate for P. 




reaction (qPCR), a sensitive detection method.131 A P. falciparum-positive sample was 
defined as a sample when florescence for both replicates crossed the threshold prior to 
the 39th cycle, or when one replicate did not amplify and the other crossed the threshold 
prior to the 39th cycle. Discordant results between duplicates were excluded from 
analysis. 
Exposure and Outcome Assessment 
Based on previous studies of malaria infection in late pregnancy, we examined 
the following predictors: maternal age, maternal height, maternal body-mass index 
(BMI), maternal education, season that coincided with the first trimester of pregnancy, 
and socioeconomic status (SES). We used the Global Network Socioeconomic Status 
Index to assess socioeconomic status.136 Developed from around 50,000 households of 
pregnant women included in the Global Network, the Socioeconomic Status Index was 
calculated by determining the sum score of 10 specific items (finished floor material, 
flush toilet, improved source of drinking water, electricity, television, smartphone, car, 
motorbike, use of liquefied petroleum gas or electricity for cooking fuel, or refrigerator) 
owned within the household.  The scores were converted to a country-specific SES 
score that ranged from 0 to 100 with higher scores indicating better housing conditions 
and more household assets.136 For predictors of maternal age, maternal height, 
maternal BMI, and socioeconomic status that were measured as continuous variables , 
we created two categories by dividing at the country-specific median based on data 
from this sub-study. Maternal education was categorized into two categories: lower (i.e., 




secondary education (7-12 years of schooling) and university and beyond education 
(≥13 years of schooling). 
The season that coincided with the first trimester of pregnancy was defined as 
rainy or not-rainy, with the specific months defined as rainy varying across countries: 
April to October in DRC,133 April to June and October to November In Kenya,134 and 
November to April in Zambia.135  
The main outcome of malaria in the first trimester was defined as P. falciparum 
positive status through qPCR in a sample obtained in the first trimester. 
Statistical Analysis 
Crude prevalence ratios (PRs) and prevalence differences (PDs) were calculated 
for malaria in the first trimester by each variable, using stratified 2x2 tables for each 
country. We present 99% confidence intervals to account for multiple comparisons and 
limit inflation of non-coverage rates.  
To assess heterogeneity by country, we calculated the I2 value. If I2 exceeded a 
pre-specified threshold of 40%,137 we did not pool results across countries to calculate a 
summary estimate. If the I2 value was ≤40%, we used the DerSimonian and Laird 
inverse variance method to calculate the summary estimate.137  
Comparisons were limited to observations without missing data for each variable. 
All analyses were conducted using the R statistical platform (version 4.0.2).  
Ethical Considerations 
The ASPIRIN trial protocol was approved by all the sites’ and partner institutions’ 
ethics review committees.18 Research personnel obtained informed consent from all 




Review Board application and received ethical approval from The University of North 
Carolina at Chapel Hill Office of Human Research Ethics, Chapel Hill, NC, USA as well 
as approval by each of the participating sites and the data coordinating center, RTI 
International. 
Results 
The ASPIRIN trial enrolled 11,953 nulliparous pregnant women in the first 
trimester; 3,800 of these were enrolled from sub-Saharan sites: 1,362 from DRC, 1,400 
from Kenya, and 1038 from Zambia. For the malaria sub-study, we analyzed a 
convenience sample of 1513 women (485 from DRC, 677 from Kenya, and 351 from 
Zambia) (Figure 4.2). Among these women, there were no missing data except for 
socioeconomic status (missing n=53).  
 Most of the nulliparous women included in this study were under 20 years of age, 
recruited before 12 weeks of gestation, and had an education level of secondary or 
university and beyond (Table 4.1). Compared to Kenyan or Zambian women, 
Congolese women were shorter, had lower BMI, and had a lower overall educational 
attainment (no secondary education). 
Population characteristics and prevalence of malaria in the first trimester 
The overall prevalence of first-trimester P. falciparum by qPCR was 38.5% 
(583/1513), though this varied by site: 62.9% (305/485 [95% CI: 58.6, 67.2]) in the DRC; 
37.8% (256/677 [95% CI: 34.2, 41.5]) in Kenya; and 6.3% (22/351 [95% CI: 3.7, 8.8]) in 
Zambia (Figure 4.1).  
Across the entire study population, compared to uninfected women, infected 




attainment (60% vs. 82% with higher education level). In addition, women with malaria 
in the first trimester were shorter in stature (155 cm vs. 157 cm), had lower weight (52 
kg vs. 54 kg), and had slightly lower BMI (21.6 kg vs. 21.9 kg) (data not shown). 
Factors correlated with malaria in the first trimester 
In Kenya, women younger than 20 years old were more likely to have malaria in 
the first trimester compared to women 20 years or older (PR = 1.57 [99% CI: 1.21, 
2.03]), with a corresponding prevalence difference of 0.17 [99% CI: 0.07, 0.26]. Also, 
Kenyan women who were 157 cm or shorter were more likely to have malaria in the first 
trimester than women taller than 157 cm [PR = 1.35 [99% CI: 1.04, 1.75]; PD = 0.11 
[99% CI: 0.02, 0.21]). There were no relationships between maternal BMI, maternal 
education, or season that coincided with the first trimester, or socioeconomic status and 
prevalence of malaria in the first trimester in Kenyan women. Similarly, in the DRC and 
Zambia, there were no statistically-significant associations between predictors 
examined and prevalence of malaria in the first trimester (Table 4.2) 
Pooling results 
For maternal education, the results of the heterogeneity assessment supported 
pooling across countries (for PD: I2 = 0 [99% CI: 0, 93]; for PR: I2 = 33 [99% CI: 0, 97]) 
(Figure 4.3). Across all three study countries, the summary prevalence difference and 
99% confidence interval indicated that lower vs. higher educational attainment was 
associated with higher prevalence of malaria in the first trimester (summary PD = 0.09 
[99% CI: 0.01, 0.17]). Although not statistically significant, we observed a consistent 
elevated summary prevalence ratio and 99% confidence interval (summary PR = 1.28 




For season during the first trimester, the results of the heterogeneity assessment 
again supported pooling (for PD: I2 = 27 [0, 96]; for PR: I2 = 0 [99% CI: 0, 94]). Across all 
three study countries, the summary prevalence difference and summary prevalence 
ratio suggested no change in prevalence of malaria in the first trimester based on the 
lack of statistical significance (summary PD = 0.00 [99% CI: -0.06, 0.06]; summary PR = 
1.06 [99% CI: 0.91, 1.23]). 
Discussion 
We are the first study to report parasite prevalence in the first trimester among a 
large number of women from sites within these three countries representing multiple 
transmission settings. The malaria in the first trimester prevalence among 485 
Congolese women was 62.9%, among 677 Kenyan women was 37.8%, and among 351 
Zambian women was 6.3%. We determined that lower overall educational attainment 
was associated with higher prevalence of malaria in the first trimester in pooled 
estimates developed from women in all three countries, and younger age and shorter 
height were associated with higher prevalence of malaria in the first trimester among 
Kenyan women. The general lack of association between parasite prevalence in the first 
trimester in primigravidae and traditional predictors suggests that routine screening may 
be necessary to mitigate the potential effects of these infections for neonates. 
When stratified by country, we found no significant association between maternal 
age or maternal height and malaria in the first trimester among Congolese or Zambian 
women, but did find that younger or shorter Kenyan women had higher prevalence of 
malaria in the first trimester. Maternal height and age have been inconsistently reported 




in Tanzania and Benin did not find an association between age or height (studied only 
among Tanzanian women) and malaria prevalence in early pregnancy.22,88 These 
studies included 121 Tanzanian women, of whom 48 were primigravidae, and 387 
Beninese women, of whom 30 were primigravidae.22,88 Compared to these previous 
studies, we had a larger sample size in Kenya (n=677) and focused on primigravidae 
which may have allowed us to detect the relationship between younger age or shorter 
height and higher prevalence of malaria in the first trimester.  
Across all three countries with different transmission intensities, we saw elevated 
prevalences of malaria in the first trimester among women with lower overall 
educational attainment (i.e. no secondary education). When we combined data from all 
three countries to develop pooled estimates, lower overall educational attainment was 
significantly associated with higher prevalence of malaria in the first trimester. These 
findings are consistent with other studies. Schmiegelow et al. had previously found this 
relationship, and we were able to confirm this association using the same education 
level comparison (i.e., primary education level or less vs. higher educational attainment) 
with a much larger sample (1513 compared to 121 women) and a more precise time 
period for malaria in the first trimester (cutoff of 14 weeks compared to 17 weeks of 
gestation).88  
When stratified by country, we did not find a significant relationship between 
lower maternal BMI, lower socioeconomic status, or rainy season coincident with the 
first trimester and higher prevalence of malaria in the first trimester. Previous studies 




early pregnancy 22,88 In contrast, these factors have been associated with higher 
prevalence of malaria in later pregnancy.7,94,95,98,99,103 
Most studies examining the relationship between age, education, and malaria in 
later pregnancy report an association between younger age or lower overall educational 
attainment and higher prevalence of malaria in later pregnancy.4,6,7,9–20 Consistent with 
findings from malaria in later pregnancy, we found that younger age was associated 
with higher prevalence of malaria in the first trimester among Kenyan women in a 
moderate malaria transmission setting, and lower overall educational attainment (no 
secondary education) was associated with higher malaria prevalence in pooled 
estimates developed from women in all three sites. In addition, short stature has been 
associated with higher prevalence of malaria in late pregnancy, and we found that 
shorter height was associated with higher malaria in the first trimester prevalence 
among Kenyan women.98 
Determining the prevalence of malaria in the first trimester can be useful to 
identify and quantify the potential problem, and identification of predictors can direct 
preventative strategies to women at highest risk. We leveraged a multi-national clinical 
trial and used qPCR, a very sensitive form of detection of malaria infection during 
pregnancy, to determine parasite prevalence and predictors of malaria in the first 
trimester among a large number of women in three countries and across multiple 
transmission settings. We also predominantly studied women with the highest risk of 
malaria in pregnancy and consequent negative health outcomes, i.e., women who were 
primigravidae.13 Over successive pregnancies, women naturally acquire resistance to 




infected erythrocytes to the placenta after a previous infection during pregnancy.12,13 
Thus, primigravid women lack this parity-dependent immunity that reduces placental 
and peripheral parasitemia.13 While we studied nulliparous women, 94% of women 
(n=1420) in our study were primigravidae.  
We were limited to data collected by the ASPIRIN trial that focused on low-dose 
aspirin, and thus did not have data to examine other malaria-specific predictors such as 
bed net use. Because pregnant women frequently have low parasite densities below the 
detection limit of common diagnostic tools, we used qPCR to detect malaria infection 
during pregnancy; however, the clinical significance of these “submicroscopic” infections 
is a matter of some debate.3–6,45 The ASPIRIN trial recruited women starting at 6 weeks 
of gestation, and thus we did not have any data on women and their malaria in the first 
trimester prevalence prior to conception or during the earliest stages of pregnancy.19 
Finally, as our study population was restricted to nulliparous women, our results on 
predictors of malaria in the first trimester cannot be generalized to all pregnant women. 
In conclusion, we found that in high-transmission settings, these first-trimester 
infections are very common, and some predictors were significant in Kenya and overall. 
Because of the differences of our findings on predictors across country, more research 
is needed on identifying actionable predictors. In the absence of consistent and practical 
predictors of malaria in the first trimester, routine screening for parasites could be 





Table 4.1: Characteristics of the study participant population, stratified by 
country 
Variable DRC KENYA ZAMBIA 
Included, N 485 677 351 
Maternal age (years), N (%) 
< 20 410 (84.5) 316 (46.7) 204 (58.1) 
20-29 68 (14.0) 356 (52.6) 144 (41.0) 
> 29 7 (1.4) 5 (0.7) 3 (0.8) 
Median (P25, P75) 18.0 (17.0, 18.0) 20.0 (18.0, 22.0) 19.0 (18.0, 21.0) 
Projected gestation age at enrollment (weeks, days), N (%) a 
6, 0 - 7, 6 50 (10.3) 115 (17.0) 40 (11.4) 
8, 0 - 9, 6 133 (27.4) 216 (31.9) 80 (22.8) 
10, 0 - 10, 6 69 (14.2) 89 (13.1) 35 (10.0) 
11, 0 - 11, 6 82 (16.9) 89 (13.1) 50 (14.2) 
12, 0 - 13, 6 151 (31.1) 168 (24.8) 146 (41.6) 
Median (P25, P75) 10.7 (9.0, 12.3) 10.0 (8.3, 11.9) 11.4 (9.1, 12.7) 
Maternal education, N (%) 
Lower 310 (63.9) 43 (6.4) 44 (12.5) 
Higher 175 (36.1) 634 (93.6) 307 (87.5) 
Maternal height (cm) 









Maternal BMI (kg/m2) 
Mean (SD) 20.8 (2.2) 23.3 (3.5) 22.0 (3.3) 
Median (P25, P75) 20.6 (19.2, 22.2) 22.8 (20.8, 25.0) 21.5 (20.0, 23.5) 
Socioeconomic status b 
Mean (SD) 13.3 (9.6) 16.7 (17.1) 43.9 (25.7) 
Median (P25, P75) 16.2 (6.2, 16.2) 8.4 (8.4, 24.6) 38.9 (25.6, 66.3) 
Season coincident with the first trimester of pregnancy, N (%) 
Rainy 244 (50.3) 211 (31.2) 174 (49.6) 
Non-rainy 241 (49.7) 466 (68.8) 177 (50.4) 
a Projected gestational age at enrollment developed from algorithm described in Hoffman et al., 2020. 
b Socioeconomic status developed using Global Network Socioeconomic Status Index described in Patel 
et al., 2020. SES was calculated by determining the sum score of the number of 10 specific items owned 




Table 4.2: Crude prevalence, crude prevalence ratio (PRs), crude prevalence differences (PDs) and 99% 
confidence intervals (CIs) for predictors of malaria in the first trimester for nulliparous women by malaria in the 
first trimester status in the Democratic Republic of Congo (DRC), Kenya, and Zambia 








































































































































































































a Median maternal age cut points (in years, younger vs. older): DRC: 18 vs. 18, Kenya: 20 vs. 20, Zambia: 19 vs. 19. 
b Median maternal height cut points (in cm, shorter vs. taller): DRC: 156 vs. 156, Kenya: 157 vs. 157, Zambia: 157 vs. 157.  
c Median maternal BMI cut points (in kg/m2, lower vs. higher): DRC: 20.6 vs. 20.6, Kenya: 22.8 vs. 22.8, Zambia: 21.5 vs. 21.5. 










Figure 4.1: Map of malaria transmission intensity based on study site 
The study locations are located in Nord-Ubangi and Sud-Ubangi provinces in the 
Democratic Republic of the Congo, in Bungoma, Busia, and Kakamega provinces in 
Kenya, and in Kafue and Chongwe districts in Lusaka province in Zambia. Malaria 
transmission is modeled from the Plasmodium falciparum parasite rate among children 
aged 2-10 (PfPR 2-10) in 2015 and ranges from 0.6 in Nord-Ubangi and Sud-Ubangi 
provinces in the Democratic Republic of the Congo to 0.0 in Lusaka province in Zambia. 








Figure 4.2: Study population of malaria predictors sub-study. 
The ASPIRIN trial included 3800 women from Democratic Republic of the Congo 
(DRC), Kenya, and Zambia. From these women, we took a convenience sample of 







14361 nulliparous pregnant women assessed for 
eligibility in ASPIRIN trial
2385 excluded from ASPIRIN trial
1534 did not meet the inclusion criteria
157 declined participation
694 did not complete the screening process
11953 included in ASPIRIN trial
3800 from Democratic Republic of the Congo 




11976 randomly assigned to low-dose aspirin or 
placebo in ASPIRIN trial
23 subsequently determined as ineligible
8153 ineligible for sub-study
1704 from Guatemala
2746 from India (Belagavi)
2072 from India (Nagpur)
1631 from Pakistan 
1513 included in malaria sub-study
485 from DRC (35.6% of eligible)
677 from Kenya (48.4% of eligible)
351 from Zambia (33.8% of eligible)







Figure 4.3: Comparison of predictors for malaria in the first trimester among 
nulliparous women from the Democratic Republic of Congo, Kenya, and Zambia 
4.3A: Comparing using prevalence differences and 4.3B comparing using prevalence 
ratios. Pink triangles are DRC, green squares are Kenya, and blue circles are Zambia. 
Summary estimates were only presented if the I2 value was less than 40%. The vertical 
grey line in the figure is the null value (0 for prevalence difference in 4.3A, 1 for 
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CHAPTER V: EFFECTS ON MATERNAL AND BIRTH OUTCOMES OF 
PLASMODIUM FALCIPARUM INFECTION IN THE FIRST TRIMESTER AMONG 
NULLIPAROUS WOMEN FROM THE DEMOCRATIC REPUBLIC OF THE CONGO, 
KENYA, AND ZAMBIA 
Chapter 5  
Introduction 
Malaria is a serious global health issue, with an estimated 228 million cases 
annually and 411,000 associated deaths worldwide in 2018.24 Nearly 85% of global 
malaria deaths occurred in 21 countries, including the Democratic Republic of the 
Congo (DRC), Kenya, and Zambia.2 In sub-Saharan Africa, 29% of all pregnancies are 
exposed to malaria infection.2 Malaria infection in pregnancy can cause maternal 
anemia, preterm birth, stillbirth, and low birth weight.1 
 To treat and prevent incident malaria infections in pregnancy, the World Health 
Organization recommends prompt diagnosis and treatment of malaria, the use of 
intermittent preventive therapy in pregnancy with sulfadoxine-pyrimethamine (IPT-SP), 
and the use of insecticide-treated nets (ITNs).2 However, these strategies are 
challenging to initiate for women early in their pregnancy and habitually leave women 
unprotected from malaria in the first trimester. For example, prompt treatment is delayed 
due to difficulties in diagnosing malaria in early pregnancy because pregnant women 
frequently have parasite densities below the detection limit of commonly available 
diagnostic tools. IPT-SP is not initiated until the second trimester because antenatal 




contraindicated in the first trimester of pregnancy because of potential teratogenic 
effects. Many pregnant women in malaria-endemic settings, especially those in their first 
pregnancy in the first trimester, do not use ITNs because of discomfort associated with 
sleeping under the ITN, difficulties in hanging the net, and lack of ownership of ITNs.3–8  
 Despite the difficulties in treatment and prevention of malaria, the first trimester 
might represent a critical time for intervention to prevent the negative consequences of 
malaria in pregnancy. Malaria in the first trimester could impact placental development 
and thus affect fetal growth.55,68,78 During the first trimester, the trophoblast invades and 
remodels the maternal uterine arteries in order to increase uterine artery blood flow.48 
Trophoblast invasion is essential for normal placental function and fetal growth, and 
occurs from very early in pregnancy until 18-20 weeks of gestation.10 However, 
placentation is particularly sensitive to pathology in the first trimester, and malaria in 
early pregnancy could inhibit trophoblast invasion and cause disruptions in 
placentation.9,10 In a study of 68 mostly multigravidae women, malaria in the first 
trimester was associated with a negative impact on placental vascular development and 
consequent pregnancy outcomes.11,12  
 Changes in placental vascularity would be even more pronounced among 
primigravidae or nulliparous women, and among women living in high malaria 
transmission areas.11 Women in their first pregnancy are particularly vulnerable to 
malaria, as women naturally acquire resistance to malaria in pregnancy in successive 
pregnancies through the development of antibodies that inhibit binding of Plasmodium 
falciparum-infected erythrocytes to the placenta.12,13 Thus, primigravid and nulliparous 




parasitemia are unable to clear placental parasites quickly leading to higher placental 
and peripheral parasitemia, and chronic placental infection, which is associated with low 
birth weight and maternal anemia.13–17 
 Research about effects of malaria in the first trimester is limited because most 
studies are limited to observations in the second trimester when women begin receiving 
antenatal care (ANC).77 Most research has focused on the birth outcomes of low birth 
weight or the maternal outcome of anemia in late pregnancy or at delivery and has 
found conflicting results for either birth outcome and the association of malaria in early 
pregnancy.4,6,11,20,39,84–86,88,92 In addition, three previous studies found conflicting results 
for the association of malaria in early pregnancy with preterm birth.4,7,92 Most prior 
studies used wide gestational age intervals to define early pregnancy instead of limiting 
to the first trimester, included mostly multigravidae women, were all single-site studies.  
 In this work, we leverage an existing, large clinical trial to develop the first multi-
country study of malaria in the first trimester among nulliparous women. Our study 
objective was to estimate the causal effect malaria in the first trimester on five maternal 
and birth outcomes: preterm delivery, small for gestational age, low birth weight, 
perinatal mortality, and anemia in late pregnancy. Based on previous work, we 
hypothesized that malaria in the first trimester would increase the prevalence of all the 
adverse maternal and birth outcomes assessed. 
Methods 
Rationale 
We previously reported the malaria in the first trimester prevalence in three sites 




participants who provided any post-baseline outcome data and who delivered at 20 
weeks of gestational age or greater. Thus, the malaria in the first trimester prevalence 
when restricted to this analysis population was 63.3% (297/469) in the DRC, 38.0% 
(244/642) in Kenya, and 6.3% (21/335) in Zambia. Since we had a large sample size of 
women from three sites with varying malaria prevalence, we had a unique chance to 
estimate the impact of malaria in the first trimester on five maternal and birth outcomes. 
Study Design and Sample 
We conducted a sub-study of the Eunice Kennedy Shriver NICHD Global 
Network for Womens’ and Children’s Health Research (GN)’s trial of low-dose aspirin 
for the prevention of preterm delivery in nulliparous women with a singleton pregnancy 
(the ASPIRIN Trial).18,19 Briefly, the ASPIRIN trial was a prospective, randomized, multi-
national clinical trial that tested the hypothesis that low-dose acetylsalicylic acid initiated 
in the first trimester reduces the risk of preterm birth.19 The trial recruited 11,920 
nulliparous women at seven research sites in six countries (DRC, Kenya, Zambia, 
Guatemala, Pakistan, and India) between March 23, 2016 and April 11, 2019, who were 
randomly assigned 1:1, beginning in the first trimester (gestational age between 6 
weeks, 0 days and 13 weeks, 6 days, confirmed by study ultrasound) and continuing 
until 36 weeks and 7 days of gestation or delivery, to receive either daily low-dose 
acetylsalicylic acid (81 mg dose) or a visually identical placebo.19  
 Women were recruited by community health workers from primary health-care 
centers and hospital-based clinics, and were screened for eligibility. Women were asked 




based on last menstrual period.18 Ultrasound was used to determine gestational age 
after enrollment.18  
 Nulliparous women were included if they were between 18-40 years of age 
(some minors were included if country-specific guidelines permitted), were residents of 
the study area, and had no more than two previous first-trimester pregnancy losses. In 
addition, all women must have had a single live intrauterine pregnancy that was 
between 6 weeks and 0 days to 13 weeks and 6 days in gestational age, confirmed by 
an early dating ultrasound. 
 Women were excluded if they were already taking daily acetylsalicylic acid for 
more than a week, if they were pregnant with multiple gestations, and if they had severe 
anemia at screening (hemoglobin < 7.0 g/dL), systolic blood pressure  140 mm Hg or 
diastolic  90 mm Hg at screening, or any medical condition that could be a 
contradiction to receiving acetylsalicylic acid (e.g., Type 1 diabetes, lupus, hypertension, 
or other significant disease), as evaluated by the site investigator.19 Further exclusion 
criteria included a fetal anomaly detected by ultrasound at screening.19 In addition, to be 
included in this analysis population assessing maternal and birth outcomes, participants 
had to provide any post-baseline outcome data and have delivered at 20 weeks of 
gestational age or greater. 
 The sub-Saharan African study sites were located in Nord-Ubangi and Sud-
Ubangi provinces in the DRC; Bungoma, Busia, and Kakamega provinces in Kenya, 





Participant Data and Sample Collection and Processing 
At enrollment, information was collected on demographics (including years of 
maternal age and education), pregnancy and medical history, and current medical 
information (including height in centimeters, weight in kilograms, blood pressure, heart 
rate, and history of diabetes).19 Dried blood spots (DBS) were also collected by pricking 
the participant’s finger and placing three blood spots on filter paper, which were then 
completely dried before storage in plastic bags with desiccant. We included all eligible 
women enrolled between January 2016 to April 2018 who consented to this sub-study. 
 DBS were shipped to the University of North Carolina in Chapel Hill, North 
Carolina, where each was retrospectively tested in duplicate for P. falciparum lactate 
dehydrogenase (pfldh) DNA using quantitative polymerase chain reaction (qPCR), a 
sensitive detection method.131 DBS were processed in chronological arrival order and a 
convenience sample was included in this analysis. A P. falciparum-positive sample was 
defined as a sample when florescence for both replicates crossed the threshold prior to 
the 39th cycle, or when one replicate did not amplify and the other crossed the threshold 
prior to the 39th cycle. Discordant results between duplicates were excluded from 
analysis. 
 Maternal and birth outcomes were obtained at delivery and up to 42 days 
following delivery using the Global Network Maternal and Newborn Health Registry.19 
Exposure, Confounder, and Outcome Assessment 
The main exposure of interest was malaria in the first trimester, defined as a 




To estimate the causal effect of malaria in the first trimester on the assessed 
maternal or birth outcome, we identified confounders of the exposure-outcome 
relationship using causal directed acyclic graphs (DAGs) based on prior knowledge.138 
As determined by the DAGs, the minimally sufficient adjustment set to estimate the total 
effect of malaria in the first trimester on any of the assessed maternal and birth 
outcomes was maternal age, maternal education, socioeconomic status, malnutrition, 
season that coincided with the first trimester, and insecticide-treated nets (ITNs). 
Maternal age was measured in years at enrollment. Maternal education was 
recorded at enrollment as no formal schooling, primary education (1-6 years of 
schooling), secondary education (7-12 years of schooling), or university and beyond 
education (≥13 years of schooling). SES was calculated using the GN Socioeconomic 
Status Index.136 Developed from around 50,000 households of pregnant women 
included in GN, the Socioeconomic Status Index is calculated by determining the sum 
score of 10 specific items owned by the household and converting to country-specific 
SES score.136 As a proxy for malnutrition, we used maternal body-mass index (BMI) at 
enrollment. Maternal BMI was calculated from the maternal weight recorded at 
enrollment in kilograms divided by the maternal height recorded at enrollment in meters 
squared. Season that coincided with the first trimester of pregnancy was defined as 
rainy or not-rainy based on the collection date recorded on the malaria DBS filter paper 
sample with the specific months defined as rainy varying across countries: April to 
October in DRC,133 April to June and October to November In Kenya,134 and November 
to April in Zambia.135 As we were limited to data collected by the ASPIRIN trial, we did 




Based on previous studies of malaria infection in late pregnancy,4,7,86 we 
examined the birth outcomes of preterm delivery, small for gestational age, low birth 
weight, and perinatal mortality and the maternal outcomes of anemia in late pregnancy 
and hypertensive disorders of pregnancy. All birth outcomes were assessed as the 
prevalence at birth. The maternal outcome of anemia in late pregnancy was assessed 
as prevalence at late pregnancy (26-30 weeks of gestation). The maternal outcome of 
hypertensive disorders was assessed as prevalence during the period from late 
pregnancy to delivery (20 weeks of gestation up until 42 days following delivery). 
The main outcome of interest, preterm birth, was defined as a stillbirth or live 
birth at or after 20 weeks and 0 days of gestation and before 37 weeks and 0 days of 
gestation.19  
Secondary birth outcomes of interest included small for gestational age, low birth 
weight, and perinatal mortality. Small for gestational age was defined as any live birth 
whose birth weight was measured within 4 days of delivery and the birth weight is below 
the INTERGROWTH 10th percentile for a given gestational age and sex of the 
newborn.19 Low birth weight was defined as a measured birthweight of < 2500 g 
measured within 4 days of delivery.19 Birthweight is the first weight of the fetus or 
newborn obtained after birth, ideally measured within the first hour of life.19 Perinatal 
mortality was defined as mortality in the perinatal period beginning at 20 completed 
weeks of gestation (154 days of gestation) and ending at seven completed days after 
birth.19 Perinatal mortality included stillbirths and deaths in the first week of life. 
Miscarriages with a gestational age of 20 week of greater were classified as stillbirths 




The secondary maternal outcome of interest included anemia in late pregnancy,  
defined as hemoglobin level <11 g/dL measured between 26-30 weeks of gestation, 
based on World Health Organization cut-offs.139 Another secondary maternal outcome 
of interest included was hypertensive disorders, defined as any of the following: (1) 2 
consecutive time points with ≥140 mm Hg systolic or ≥90 mm Hg diastolic where those 
two timepoints occur more than 7 days apart. The criteria (i.e., elevated systolic or 
elevated diastolic) must be consistent for the two consecutive visits or (2) Have 
evidence of hypertensive disease such as: any reported severe adverse event of 
preeclampsia or eclampsia, Maternal and Newborn Health registry report of 
hypertensive disease, preeclampsia or eclampsia, or reports of elevated blood pressure 
that meet the criteria based on the American College of Obstetricians and 
Gynecologists 2013 “Hypertension in Pregnancy” Task Force Report at any point after 
20 weeks of gestation AND have at least one report of elevated blood pressure that is 
not followed by a normal value, in which case their outcome classification was decided 
by masked clinical experts19 
Statistical Analyses 
The analysis population included all randomized participants who provided any 
post-baseline outcome data and who delivered at 20 weeks of gestational age or 
greater. This restriction on the data analysis was performed in recognition that missing 
data were likely to occur because of miscarriage or medical termination of pregnancy.19 
Because of this restriction on the data analysis, we determined prevalences of all birth 
outcomes, and the prevalence of anemia in late pregnancy and the prevalence of 





Crude prevalence ratios (PRs) and prevalence differences (PDs) were calculated 
for each maternal and birth outcome by malaria in the first trimester, using stratified 2x2 
tables for each country. We present 99% confidence intervals to account for multiple 
comparisons. We did not calculate the crude prevalence ratio if there were no cases of 
the outcome when stratified by malaria in the first trimester exposure and country. 
 To assess whether the results from each country were too heterogeneous to 
combine, we calculated the I2 value. If I2 exceeded a pre-specified threshold of 40%,137 
we did not pool results across countries to calculate a summary estimate. If the I2 value 
was ≤40%, we used the DerSimonian and Laird inverse variance method to calculate a 
summary estimate.137 We did not pool results of any outcome that had zero participants 
in at least one of the cells when stratified by malaria in the first trimester exposure and 
country. 
Confounder identification and specification 
After using DAGs to identify potential confounders, we determined that the 
minimally sufficient adjustment set to estimate the total effect of malaria in the first 
trimester on any of the assessed maternal and birth outcomes was maternal age, 
maternal education, socioeconomic status (SES), malnutrition, season that coincided 
with the first trimester of pregnancy, and insecticide-treated nets (ITNs). As a proxy for 
malnutrition, we used maternal body-mass index (BMI) at enrollment.141 
To model the continuous covariates of maternal age, BMI, and SES, we used 
restricted cubic splines with four knots at the 5th, 35th, 65th, and 95th percentile to 




identical and so we used restricted cubic splines with three knots at the 5th, 50th, and 
95th percentiles. Maternal education was categorized into two categories: lower (no 
more than primary education (1-6 years of schooling)), and higher (at least some 
secondary education (7-12 years of schooling) or university and beyond education (≥13 
years of schooling)). Season that coincided with the first trimester of pregnancy was 
either rainy or non-rainy. Because we were limited to data collected by the ASPIRIN 
trial, we did not have data on ITNs and did not adjust for ITN use in our causal model. 
Adjusted effects 
Our main analytic approach was parametric g-computation.142 We estimated the 
average causal effect of malaria in the first trimester on the assessed maternal or birth 
outcome. We used parametric g-computation to determine the predicted outcomes 
given the all participants had the exposure of malaria in the first trimester and the 
predicted outcomes given all participants did not have the exposure of malaria in the 
first trimester.  
We initially attempted to use linear binomial models to estimated adjusted 
prevalence difference and log-binomial to estimated adjusted prevalence ratios. 
However, our models did not converge, so we instead used logistic regression as our 
model as logistic regression always converges and provides a probability within 0 and 1. 
We first modeled the association of malaria in the first trimester and the 
assessed maternal or birth outcome. We used logistic regression and adjusted for 
confounders identified by the DAG. We estimated the parameter coefficients of the 
model, and then predicted the mean outcome given everyone was exposed and given 




outcomes for the combination of values for the confounders included, i.e., the 
standardized outcome.  
Our logistic regression model provided the predicted outcomes as the predicted 
log-odds. We converted these predicted log-odds to estimated mean prevalences by 
first exponentiating the predicted log odds to obtain predicted odds, and then as 
prevalence is equal to odds divided by the denominator of odds plus 1, calculating the 
predicted prevalences from the predicted odds. We then took the mean of the predicted 
prevalences to estimate the mean prevalence of the outcome given everyone was 
exposed to malaria in the first trimester and given everyone was unexposed. From 
these mean prevalence estimates, we calculated the adjusted prevalence ratios (aPRs) 
and adjusted prevalence differences (aPDs). We then used bootstrapping with 10,000 
repetitions to determine their corresponding 99 percentile confidence intervals by 
selecting the 50th ordered value as the lower limit and 9950th ordered value as the upper 
limit.  
We thus calculated the adjusted effect of malaria in the first trimester on the 
assessed outcome. However, our goal was to estimate the causal effect of malaria in 
the first trimester on adverse maternal and birth outcomes. In order to interpret our 
results of our g-computation approach as an estimate of the average causal effect, we 
would need to assume counterfactual consistency, exchangeability, and positivity.142 
Counterfactual consistency requires that the observed outcomes among those who 
were exposed (or not) is equal to the potential outcomes that would be observed given 
they were exposed (or not).142 Exchangeability exists when the potential outcomes 




assumption could be met by conditional mean exchangeability (i.e., the potential 
outcomes were independent of the observed exposure given the covariates). 
Conditional mean exchangeability assumes that all confounding has been controlled in 
the model.142 The final assumption of positivity requires a non-zero probability for all 
values of exposure (i.e., malaria in the first trimester or not) conditional on the variables 
required for conditional mean exchangeability.142 These assumptions of counterfactual 
consistency, conditional mean exchangeability, and positivity must be met before we 
could interpret the adjusted effects of malaria in the first trimester on the assessed 
outcome as an estimate of the average causal effect. 
 In our model, trial arm was randomly allocated without respect to malaria in the 
first trimester status and was thus we did not need to control for the effects of the 
ASPIRIN study protocol. We did not adjust for malaria in late pregnancy as it is on the 
causal pathway of malaria in the first trimester and any of the assessed outcomes. As 
we were limited to data collected by the ASPIRIN trial, we did not have data on ITNs 
and did not adjust for ITN use in our causal model. 
 Comparisons were limited to observations without missing data for each variable, 
and models were limited to observations without missing data for all covariates and the 
outcome. All analyses were conducted using the R statistical platform (version 4.0.2).126 
Ethical Considerations 
The ASPIRIN trial protocol and malaria sub-study were approved by all the sites’ 
and partner institutions’ ethics review committees.18 Research personnel obtained 





Population characteristics and prevalence of malaria in the first trimester  
The ASPIRIN trial enrolled 11,953 nulliparous pregnant women in the first 
trimester; 3,800 of these were enrolled from sub-Saharan sites: 1,362 from DRC, 1,400 
from Kenya, and 1,038 from Zambia. For the malaria analysis sub-study, we analyzed a 
convenience sample of 1,446 women (469 from DRC, 642 from Kenya, and 335 from 
Zambia) (Figure 5.2). 
There were no missing data for preterm birth, or perinatal mortality. There were 
92 (6.4% of total sample) women missing data for small for gestational age, 49 (3.4% of 
total sample) missing data for low birth weight, and 195 (13.5%) missing data for 
anemia in late pregnancy. There were no missing covariate data except for 40 (2.8% of 
total sample) women missing socioeconomic status. 
 Most of the nulliparous women included in this study were under 20 years of age, 
recruited before 12 weeks of gestation, and had at least some secondary education 
(Table 5.1). Congolese women were younger, shorter, had lower BMI, and had lower 
educational attainment compared to Kenyan or Zambian women. Most women had a 
nurse or midwife as a delivery attendant, delivered at a clinic or health center, and had a 
vaginal delivery. 
Prevalence of adverse maternal and birth outcomes 
The prevalence of preterm birth was highest in DRC (19.6%), lower in Kenya 
(9.0%), and lowest in Zambia (6.9%). Similarly, the prevalence of anemia in late 
pregnancy was highest in DRC (56.8%), lower in Kenya (35.5%), and lowest in Zambia 




(32/469) in DRC, 5.3% (34/642) in Kenya, and 5.4% (18/335) Zambia. Small for 
gestational age prevalence was high for both DRC (15.8%) and Zambia (14.3%) and 
lower for Kenya (8.7%). The prevalence of low birth weight was 17.2% (79/458) in DRC, 
5.9% (36/609) in Kenya, and 9.1% (30/330) in Zambia. The prevalence of the maternal 
birth outcome of hypertensive disorders was very low: 0.2% (1/469) DRC, 0.8% (5/642) 
in Kenya, and 3.9% (13/335) in Zambia. 
Crude association of malaria in the first trimester on maternal and birth outcomes 
In the DRC, the crude prevalence of preterm birth (PD = 0.06 [99% CI: -0.03, 
0.16]) and of low birth weight (PD = 0.07 [99% CI: -0.02, 0.16]) was elevated among 
women with malaria in the first trimester compared to women without malaria in the first 
trimester In Kenya, we saw higher crude prevalence of preterm birth (PD = 0.03 [99% 
CI: -0.03, 0.10]) and of anemia in late pregnancy (PD = 0.10 [99% CI: -0.01, 0.21]) 
among women with malaria in the first trimester. In Zambia, we found significant lower 
crude prevalence of perinatal mortality (PD = -0.06 [99% CI: -0.09, -0.02]). However, 
none of the 21 Zambian women with malaria in the first trimester had the birth outcome 
of perinatal mortality (Table 5.2). 
 We did not pool results from perinatal mortality because at least one of the 
countries had no cases of the outcome when stratified by malaria exposure. The results 
of the heterogeneity assessment supported pooling across countries for the crude 
prevalence ratio and crude prevalence difference for preterm birth, small for gestational 
age, and anemia in late pregnancy, and for the crude prevalence ratio for low birth 




 Malaria in the first trimester was associated with a higher prevalence of preterm 
birth among women from DRC, Kenya, and Zambia (summary PD = 0.03 [99% CI: -
0.02, 0.08]). We observed a consistent elevated summary prevalence ratio and 99% 
confidence interval (summary PR = 1.38 [99% CI: 0.92, 2.07]). Malaria in the first 
trimester was not associated with changes in the prevalence of small for gestational age 
among women from all three sites (summary PD = -0.02 [99% CI: -0.07, 0.03]; summary 
PR = 0.87 [99% CI: 0.57, 1.33]). Malaria in the first trimester was associated with higher 
prevalence of low birth weight among women when pooled together (summary PR = 
1.47 [99% CI: 0.91, 2.38]); the heterogeneity assessment did not support pooling for the 
low birth weight prevalence difference. Finally, malaria in the first trimester was 
associated with higher prevalence of anemia in late pregnancy (summary PD = 0.08 
[99% CI: 0.00, 1.16]). We observed an elevated summary prevalence ratio for anemia 
(summary PR = 1.21 [99% CI: 0.95, 1.56]) (Table 5.3). 
Adjusted effect of malaria in the first trimester on maternal and birth outcomes 
After adjustment for age, education, socioeconomic status, malnutrition (with 
enrollment BMI at enrollment as a proxy), and season coincident with the first trimester 
as suggested by the DAG (Figure 5.3), we found higher prevalence of preterm delivery 
among Congolese women (aPD = 0.06 [99% CI: -0.04, 0.16]) but not among Kenyan 
(aPD = 0.03 [-0.04, 0.09]) or Zambian women (aPD = -0.01 [99% CI: -0.10, 0.20]) who 
had malaria in the first trimester compared to women who did not. We also saw an 
elevated prevalence of low birth weight among Congolese women (aPD = 0.07 [99% CI: 
-0.03, 0.16]) but not among Kenyan (aPD = 0.01 [-0.04, 0.06] or Zambian (aPD = -0.04 




The prevalence of anemia in late pregnancy also was slightly higher among 
Kenyan (aPD = 0.05 [99% CI: -0.06, 0.17]), Zambian (aPD = 0.07 [99% CI: -0.12, 0.36]), 
and Congolese women (aPD = 0.04 [99% CI: -0.09, 0.16]) with malaria in the first 
trimester. In Zambia, we found a significantly lower prevalence of perinatal mortality 
among women with malaria in the first trimester (aPD = -0.06 [99% CI: -0.09, -0.03]), 
however all Zambian women who had malaria in the first trimester (n=21) did not have 
perinatal mortality. We did not find an effect of malaria in the first trimester on perinatal 
mortality among Congolese (aPD = 0.02 [99% CI: -0.04, 0.08]) or Kenyan women (aPD 
= 0.03 [99% CI: -0.02, 0.08]) (Table 5.4). 
Discussion 
We are the first study to estimate the effect of malaria in the first trimester on 
maternal and birth outcomes among a large number of women from multiple African 
countries and transmission settings. We found higher prevalences of preterm delivery 
and low birth weight among Congolese women with malaria in the first trimester, and 
higher prevalence of anemia in late pregnancy among Kenyan, Zambian, and 
Congolese women who had malaria in the first trimester. We additionally found a 
significantly lower prevalence of perinatal mortality among Zambian women with malaria 
in the first trimester, but all Zambian women with malaria in the first trimester did not 
have perinatal mortality, and we did not find this association among Congolese or 
Kenyan women. 
 Among the three study sites, we found higher prevalence of preterm delivery 
among Congolese and Kenyan women, but not among Zambian women with malaria in 




preterm delivery suggest conflicting relationships. Two studies assessing malaria before 
24 weeks of gestation found an increased risk of preterm delivery7 or an increased odds 
of preterm delivery among multigravidae only.4 The last study assessed malaria in the 
first trimester among 273 Beninese women (of which 7.4% were primigravidae) and 
found no association with preterm birth.92 We also used malaria in the first trimester as 
our exposure window but we focused primarily on primigravidae and had larger 
numbers of pregnant women followed in all three sites. We may have been able to 
detect a weak association between malaria in the first trimester and preterm delivery 
because DRC and Kenya had high malaria transmission (malaria in the first trimester 
prevalence 63.3% in DRC and 38.0% in Kenya), we focused on women who were the 
most vulnerable to malaria infection, and included large numbers of women in our 
analysis (469 in DRC and 642 in Kenya). 
We additionally found higher prevalence of low birth weight among Congolese 
women with malaria in the first trimester, but not among Kenyan or Zambian women 
with malaria in the first trimester. While multiple studies have assessed the association 
of malaria in early pregnancy and low birth weight, the relationship is still unclear, with 
several finding higher risk and others finding no association.11,85,92 Moeller et al. found 
an association of malaria infection before 15 weeks of gestation and lower birth weight 
among 138 Tanzanian women,11 McGready et al., found no association of malaria in the 
first trimester infection (of either P. falciparum or vivax) and birth weight among 17,613 
women who lived along the Thai Burmese border85 and Accrombessi et al. also found 
no association of malaria in the first trimester infection and birth weight among 273 




pregnancy (i.e., primigravidae) and the high malaria transmission burden may have 
allowed us to detect an association between malaria in the first trimester and higher 
prevalence of low birth weight among Congolese women.  
Across all three countries with different transmission intensities, we saw elevated 
crude and adjusted prevalences of anemia in late pregnancy among women with 
malaria in the first trimester. We also found a significantly higher prevalence in anemia 
in late pregnancy among women with malaria in the first trimester in the pooled crude 
prevalence difference (with a consistent elevated pooled prevalence ratio). Most 
previous research assessing the association of malaria in early pregnancy and maternal 
anemia in late pregnancy or at delivery have found higher risk of the outcome, with only 
one study finding no association.4,20,86,88,92 Our results confirm these findings although 
we did not see significantly higher crude or adjusted prevalences of anemia in late 
pregnancy when stratified by country. However, as our study population was restricted 
to women without severe maternal anemia (<7 g/dL) at enrollment, our findings were 
biased towards a null relationship and are non-generalizable to all nulliparous women. 
 We saw significant crude and adjusted lower prevalences of perinatal mortality 
among Zambia women with malaria in the first trimester. Only one study (in Burkina 
Faso) has assessed the association of malaria in the first trimester and perinatal 
mortality, and as no women with malaria in the first trimester had perinatal mortality and 
they were using incidence rate ratios, they did not calculate an effect measure.86 
Similarly, we also had few women in Zambia who had malaria in the first trimester (31 
out of 1034 women from Burkina Faso and 21 out of 351 women from Zambia in our 




none had perinatal mortality.86 However, as we calculated both prevalence ratios and 
prevalence differences, we were able to calculate the prevalence difference despite 
zero outcomes of perinatal mortality among Zambian women with malaria in the first 
trimester. While we did find a significant association between malaria in the first 
trimester and lower prevalence of perinatal mortality among Zambia women, we did not 
find this association among Congolese or Kenyan women. Due to low numbers of 
Zambian women with malaria in the first trimester and possible selection bias caused by 
restricting the study population to women who delivered at 20 weeks of gestational age 
or greater, this result among Zambian women has strong limitations to reliability. 
Similar to previous research on small for gestational age and malaria in early 
pregnancy (i.e., gestational age between 4-12 weeks, before 15 weeks, and before 24 
weeks), we did not find an association between malaria in the first trimester and 
prevalence of small for gestational age.7,10,92 No studies have assessed the association 
of malaria in early pregnancy and hypertensive disorders, and while we found a 
significantly lower crude prevalence of hypertensive disorders among Zambian women 
with malaria in the first trimester, all Zambia women with malaria in the first trimester did 
not have hypertensive disorders. The prevalence of hypertensive disorders was very 
low for all three countries ranging from 0.2% in DRC to 3.4% in Zambia, and thus we did 
not estimate the adjusted effect of malaria in the first trimester on hypertensive 
disorders. 
A strength of this study was that we predominantly studied women with the 
highest risk of malaria in pregnancy and consequent negative health outcomes, i.e., 




women naturally acquire resistance to malaria in pregnancy by developing antibodies 
that inhibit binding of P. falciparum-infected erythrocytes to the placenta after a previous 
infection during pregnancy.12,13 Thus, primigravidae lack this parity-dependent immunity 
that reduces placental and peripheral parasitemia.13,44 While we studied nulliparous 
women, most (94%) of the women in our study were primigravidae.  
 Our study used DAGs as a framework to describe the causal relationship 
between the exposure of malaria in the first trimester and the adverse maternal or birth 
outcome. Based on these DAGs, the minimally sufficient adjustment set to estimate the 
total effect of malaria in the first trimester on any of the assessed maternal and birth 
outcomes was age, education, SES, season that coincided with the first trimester of 
pregnancy, malnutrition (used BMI as a proxy), and ITN use. We were limited to data 
collected by the ASPIRIN trial that focused on low-dose acetylsalicylic acid, and thus did 
not have data on ITN. However, as many pregnant women acquire ITNs through their 
first antenatal care visit, and women rarely use ITNs before and during their first 
pregnancy, the impact of ITN use on malaria in the first trimester among nulliparous 
women is likely to be low.8,21,23  
 Another strength was our use of the parametric g-computation to estimate the 
average causal effect of malaria in the first trimester on the assessed maternal and birth 
outcome. Using log binomial models to calculate adjusted prevalence differences 
frequently face issues with convergence. We instead used logistic regression as our 
model as logistic regression always converges.  We were able to convert the predicted 
log-odds of outcome given everyone had malaria in the first trimester (or everyone was 




first trimester (or everyone was not exposed). From these predicted prevalences, we 
took the mean to estimate the mean prevalence of the outcome given everyone was 
exposed (or not), and then calculated adjusted prevalence ratios and adjusted 
prevalence differences.  
We thus estimated the adjusted effect of malaria in the first trimester on the 
assessed outcome. However, our goal was to estimate the causal effect of malaria in 
the first trimester on adverse maternal and birth outcomes. In order to interpret our 
results of our g-computation approach as an estimate of the average causal effect, we 
would need to assume counterfactual consistency, exchangeability, and positivity.142 
While we used the DAGs to identify confounders and adjusted for all confounders 
included in the ASPIRIN dataset, we did not adjust for ITNs or other unmeasured 
confounders.  
Thus, we cannot assume that we had conditional mean exchangeability. 
Consequently, we also cannot assume that there is a non-zero probability of all values 
of the exposure conditional on the variables required for conditional mean 
exchangeability as we cannot justify our identifying and measuring all variables required 
for conditional mean exchangeability. Therefore, while our goal was to estimate the 
average causal effect of malaria in the first trimester on maternal and birth outcomes, 
we can only interpret our results as the adjusted effect of malaria in the first trimester on 
the assessed outcome. 
 In the first, large multi-site study of malaria in the first trimester, we used an 
efficient study design nested within a large clinical trial to estimate the effect of malaria 




settings among a large number of nulliparous women. We found higher prevalence of 
preterm delivery and low birth weight among Congolese women, and higher prevalence 
in the prevalence of anemia in late pregnancy among Congolese, Kenyan, and Zambian 
women.  
 In conclusion, we found that in these first-trimester infections are very common in 
high transmission settings and can lead to non-significant higher prevalence in preterm 
delivery, low birth weight, and anemia in late pregnancy. The higher prevalences of 
adverse maternal and birth outcomes associated with malaria in the first trimester 
suggest that strategies including screening in the first trimester are needed to reduce 
the impact of malaria in the first trimester. 
 
  




Table 5.1: Characteristics of the study participant analysis population, stratified 
by country 
Variable DRC KENYA ZAMBIA 
Randomized, N 469 642 335 
Maternal age (years), N (%) 
< 20 396 (84.4) 298 (46.4) 196 (58.5) 
20-29 66 (14.1) 340 (53.0) 136 (40.6) 
> 29 7 (1.5) 4 (0.6) 3 (0.9) 
Median (P25, P75) 18.0 (17.0, 18.0) 20.0 (18.0, 22.0) 19.0 (18.0. 21.0) 
Projected gestation age at enrollment (weeks, days), N (%) a 
6, 0 - 7, 6 44 (9.4) 110 (17.1) 37 (11.0) 
8, 0 - 9, 6 127 (27.1) 198 (30.8) 74 (22.1) 
10, 0 - 10, 6 68 (14.5) 86 (13.4) 33 (9.9) 
11, 0 - 11,6 81 (17.3) 85 (13.2) 49 (14.6) 
12, 0 - 13, 6 149 (31.8) 163 (25.4) 142 (42.4) 
Median (P25, P75) 10.9 (9.1, 12.3) 10.1 (8.3,12.0) 11.4 (9.1, 12.7) 
Maternal education, N (%) 
No formal 76 (16.2) 1 (0.2) 11 (3.3) 
Primary 226 (48.2) 42 (6.5) 31 (9.3) 
Secondary 166 (35.4) 520 (81.0) 289 (86.3) 
University + 1 (0.2) 79 (12.3) 4 (1.2) 
Maternal height (cm) 
Mean (SD) 155.8 (6.6) 156.2 (8.8) 157.5 (6.4) 
Median (P25, P75) 156.0 (151.0, 160.0) 157.1 (150.0, 162.4) 157.0 (154.0, 161.0) 
Maternal weight (kg) 
Mean (SD) 50.5 (6.7) 56.4 (7.4) 54.6 (8.8) 
Median (P25, P75) 50.0 (46.0, 55.0) 56.0 (51.0, 61.0) 54.0 (49.0, 59.0) 
Maternal BMI (kg/m2) 
Mean (SD) 20.8 (2.2) 23.3 (3.5) 22.0 (3.3) 
Median (P25, P75) 20.5 (19.1, 22.1) 22.8 (20.8, 25.0) 21.6 (20.0, 23.5) 
Antenatal care visits 
Mean (SD) 3.7 (1.1) 4.4 (1.3) 4.0 (0.8) 
Median (P25, P75) 4.0 (3.0, 4.0) 4.0 (4,0, 5.0) 4.0 (4.0, 4.0) 
Delivery attendant, N (%) 
Physician 11 (2.3) 25 (3.9) 24 (7.2) 
Nurse/nurse 
midwife 






42 (9.0) 47 (7.3) 5 (1.5) 
Family/Self/Other 7 (1.5) 20 (3.1) 11 (3.3) 
Delivery location, N (%) 
Hospital 62 (13.2) 141 (22.0) 136 (40.6) 
Clinic/health 
center 
350 (74.6) 406 (63.2) 184 (54.9) 
Home/Other 57 (12.2) 95 (14.8) 15 (4.5) 
Delivery mode, N (%) 
Vaginal 460 (98.1) 618 (96.3) 317 (94.6) 
C-section 9 (1.9) 24 (3.7) 18 (5.4) 




Table 5.2: Crude prevalence, prevalence ratios (PRs), crude prevalence differences (PDs), and 99% confidence 
intervals (CIs) for maternal and birth outcomes for nulliparous women by malaria in the first trimester status from 
the Democratic Republic of Congo, Kenya, and Zambia 














































































































































































































Table 5.3: Crude pooled prevalence ratios (pooled PRs), crude pooled prevalence differences (pooled PDs), 99% 
confidence intervals (CIs), and corresponding I2 values and 99% CI for maternal and birth outcomes for 
nulliparous women by malaria in the first trimester status from the Democratic Republic of Congo, Kenya, and 
Zambia 
 I2 (99% CI) Pooled PR (99% CI) I2 (99% CI) Pooled PD (99% CI) 
Preterm birth 
Malaria + vs. Malaria - 0.0% (0.0, 80.4) 1.38 (0.92, 2.07) 0.0% (0.0, 94.7) 0.03 (-0.02, 0.08) 
Small for gestational age 
Malaria + vs. Malaria - 0.0% (0.0, 27.8) 0.87 (0.57, 1.33) 0.0% (0.0, 49.8) -0.02 (-0.07, 0.03) 
Low birth weight 
Malaria + vs. Malaria - 0.0% (0.0, 91.7) 1.47 (0.91, 2.38) 48.9% (0.0, 89.9) NA 
Anemia in late pregnancy 







Table 5.4: Adjusted prevalence ratios (aPRs), adjusted prevalence differences (aPDs), and 99% confidence 
intervals (CIs) for maternal and birth outcomes for nulliparous women by malaria in the first trimester status in 
the Democratic Republic of Congo, Kenya, and Zambia 
 DRC KENYA ZAMBIA 
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Low birth weight 


























Anemia in late pregnancy 













Note: All models were adjusted for age, education, socioeconomic status, season coincident with the first trimester, and body-mass 
index. 







Figure 5.1: Map of malaria transmission intensity based on study site 
The study locations are located in Nord-Ubangi and Sud-Ubangi provinces in the 
Democratic Republic of the Congo, in Bungoma, Busia, and Kakamega provinces in 
Kenya, and in Kafue and Chongwe districts in Lusaka province in Zambia. Malaria 
transmission is modeled from the Plasmodium falciparum parasite rate among children 
aged 2-10 (PfPR 2-10) in 2015 and ranges from 0.6 in Nord-Ubangi and Sud-Ubangi 
provinces in the Democratic Republic of the Congo to 0.0 in Lusaka province in Zambia. 






Figure 5.2: Study population of malaria analysis sub-study 
The ASPIRIN trial included 3800 women from Democratic Republic of the Congo 
(DRC), Kenya, and Zambia. From these women, we took a convenience sample of 
1446 women for the analysis population of the malaria sub-study: 469 from DRC, 642 
from Kenya, and 335 from Zambia. 
 
  
4501 nulliparous pregnant women screened for 
eligibility in ASPIRIN trial from Democratic Republic 
of the Congo (DRC), Kenya, and Zambia
691 excluded from ASPIRIN trial
657 did not meet the inclusion criteria
11 declined participation
23 did not complete the screening process
3800 included in ASPIRIN trial
3810 randomly assigned to low-dose aspirin or 
placebo in ASPIRIN trial
10 subsequently determined as ineligible




1446 included in malaria sub-study
469 from DRC (35.5% of eligible)
642 from Kenya (48.3% of eligible)
335 from Zambia (33.2% of eligible)




142 excluded from ASPIRIN trial analysis
111 with a pregnancy outcome at <20 weeks
31 lost to follow-up prior to delivery
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Figure 5.3: DAG of the relationship between the exposure of malaria in the first 
trimester and the outcome of preterm birth 
The minimally sufficient adjustment set to determine the total effect of malaria in the first 
trimester on preterm birth is season coincident with the first trimester, age, education, 
socioeconomic status (SES), malnutrition (used a proxy of maternal BMI), and 










CHAPTER VI: CONCLUSIONS 
 
Summary of Findings 
This dissertation was motivated by the current gap in the literature studying 
malaria in the first trimester. Although the first trimester might represent a critical time 
for intervention to prevent the negative consequences of malaria in pregnancy, few 
studies have studied malaria in the first trimester. We characterized what factors are 
associated with increased likelihood of malaria in the first trimester and estimated 
causal effects of malaria in the first trimester on adverse maternal and birth outcomes. 
We hypothesized that lower overall educational attainment (no secondary education) 
would be associated with increased likelihood of malaria in the first trimester, and that 
malaria in the first trimester would increase the prevalence of all the adverse maternal 
and birth outcomes assessed. Malaria in the first trimester was studied among a large 
number of women from sites within three countries with different malaria transmission 
levels among nulliparous women.  
This study was nested within the NICHD Global Network’s trial of low-dose 
aspirin for the prevention of preterm delivery in nulliparous women with a singleton 
pregnancy (the ASPIRIN Trial). The ASPIRIN trial recruited nulliparous women in their 
first trimester between March 2016 and April 2019 at seven research sites in six 
countries, including three in sub-Saharan Africa: Democratic Republic of the Congo, 
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Kenya, and Zambia. Dried blood spots were collected from participants at enrollment 
and were retrospectively tested for Plasmodium falciparum parasites. After linking 
quantitative polymerase chain reaction results on malaria in the first trimester to extant 
ASPIRIN trial data, we used crude and pooled effect measures to determine predictors 
of malaria in the first trimester and used the parametric g-computation and directed 
acyclic graphs to estimate its effects on maternal and birth outcomes. 
 For the predictors of malaria in the first trimester in Aim 1, we found the 
prevalence of malaria in the first trimester varied across sites: 62.9% in the DRC, 37.8% 
in Kenya, and 6.3% in Zambia. Consistent with our hypothesis, we found that lower 
overall educational attainment was associated with higher prevalence of malaria in the 
first trimester in pooled estimates developed from women in all three countries. We also 
found that younger age and shorter height were associated with higher prevalence of 
malaria in the first trimester among Kenyan women.  
 For the effects on maternal and birth outcomes of malaria in the first trimester in 
Aim 2, we found higher prevalences of preterm delivery and low birth weight among 
Congolese women with malaria in the first trimester, and higher prevalence of anemia in 
late pregnancy among Kenyan, Zambian, and Congolese women who had malaria in 
the first trimester. We additionally found a significantly lower prevalence of perinatal 
mortality among Zambian women with malaria in the first trimester, but all Zambian 
women with malaria in the first trimester did not have perinatal mortality, and we did not 
find this association among Congolese or Kenyan women. 
 The dissertation findings suggest that the burden of malaria in the first trimester 
varies greatly by site and differences in findings on predictors varied by country. 
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However, when pooled across all three sites, lower overall educational attainment was 
associated with higher prevalence of malaria in the first trimester. In addition, in areas of 
high transmission, women who had malaria in the first trimester had higher prevalences 
of adverse birth outcomes, and in all three sites regardless of transmission intensity, 
malaria in the first trimester was associated with higher prevalence of anemia in late 
pregnancy. This research provides a rationale to conduct more research identifying 
actionable predictors and to improve prevention and treatment of malaria among 
women in their first trimester 
Strengths and Limitations 
 Strengths and limitations of each aim are detailed below across five areas in 
epidemiology: confounding, measurement, missingness, selection, and generalizability.  
Confounding  
For the first aim of predictors, we calculated crude and pooled crude associations 
of the assessed predictor and malaria in the first trimester. As we were determining only 
the marginal associations, we did not need to control for confounding variables.  
For the second aim of maternal and birth outcomes, we used DAGs to identify 
the minimally sufficient adjustment set of covariates. Our goal was to estimate the 
causal effect of malaria in the first trimester on adverse maternal and birth outcomes. In 
order to interpret our results of our g-computation approach as an estimate of the 
average causal effect, we would need to assume mean conditional exchangeability (i.e., 
the potential outcomes were independent of the observed exposure given the 
covariates). While we used DAGs to identify confounders and adjusted for all 
confounders included in the ASPIRIN dataset, we did not adjust for ITNs or other 
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unmeasured confounders. Thus, we cannot assume that we had conditional mean 
exchangeability.  
Measurement 
In both aims, we used a qPCR assay to detect malaria in the first trimester, but 
as pregnant women frequently have very low parasitemia levels, it is possible we did not 
detect some infections. However, PCR is very sensitive and can detect infections 
missed by common diagnostic tools such as RDTs and microscopy. However, the 
clinical significance of these subpatent or submicroscopic infections is still a matter of 
some debate.36,45 While the outcome was malaria infection in the first trimester, as 
qPCR is able to detect very low levels of parasite nucleic acids, we could have detected 
residuals from a non-viable sequestered parasite.36 
In Aim 1, we assessed the predictors of maternal age, maternal height, maternal 
BMI, maternal education, socioeconomic status, and season coincident with the first 
trimester. The first five of the above listed predictors were recorded by the ASPIRIN trial 
at enrollment. This data which was reported by each of the sites to the Global Network 
Data Coordinating Center (RTI International) who validated a random 5% of the actual 
data collected by chart review to ensure data quality. 
We may have misclassified maternal BMI at enrollment as it is calculated using 
maternal weight which increases over pregnancy. While maternal weight was recorded 
between 6 weeks 0 days and 13 weeks 6 days of gestational age, pregnant women who 
were enrolled later in gestational age could have had increased maternal weight due to 
pregnancy. However, any measurement bias is likely minimal as women were enrolled 
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in the first trimester and thus before women in resource-limited countries typically gain 
significant weight due to pregnancy.144  
The birth outcome of hypertensive disorders included diagnosis of preeclampsia 
at the time of birth admission which was determined by measuring blood pressure and 
evaluating proteinuria. However, at the clinics and health centers included in this study, 
assessing blood pressure and proteinuria was frequently not routine procedure for birth 
admission, leading to women with preeclampsia being misclassified as women without 
preeclampsia. However, to address this misclassification, the definition of hypertension 
was intentionally wide to try to capture some of these misclassified women. 
Missingness 
Across the two aims, a convenience sample of DBS were processed and 
included in the analysis. Therefore, between one-third to one-half of participants who 
were eligible for this sub-study were included in our data analysis. In addition, we further 
restricted the study population from Aim 1 to only include women who provided any 
post-baseline outcome data and who delivered at 20 weeks of gestational age or 
greater for Aim 2. While we did not assess the malaria in the first trimester status of 
those not included in our convenience sample or the effects of malaria in the first 
trimester among those who delivered before 20 weeks of gestational age, our study 
population numbers were reasonably large compared to previous studies. 
In addition, for both aims, we used complete case analysis and thus limited 
comparisons and models to observations without missing data for each variable and 
covariate. For Aim 1, there were no missing data except for socioeconomic status 
(missing n=53), and similarly for Aim 2, there were no missing covariate data except for 
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socioeconomic status (missing n=40). However, for Aim 2, while there were no missing 
data for preterm birth, perinatal mortality, or hypertension, 6% of women were missing 
data for small for gestational age, 3% for low birth weight, and 13.5% for anemia in late 
pregnancy. Thus, it is possible that these birth outcomes were not missing completely at 
random, and thus we may have produced biased estimates, especially for anemia in 
late pregnancy. 
Selection 
Selection criteria for the ASPIRIN trial included women who had no more than 
two previous first-trimester pregnancy losses and excluded women with multiple 
gestations, severe anemia at screening, and hypertensive disorders at screening. By 
excluding women with more than two previous first-trimester pregnancy losses, we likely 
excluded women with a higher likelihood of miscarrying before 20 weeks of gestation. 
Thus, we likely reduced the number of women included at enrollment who were 
excluded from the analysis population because they did not deliver at 20 weeks of 
gestation or greater. Also, women with multiple gestations are more likely to have birth 
complications, and thus we likely reduced the overall prevalence of adverse birth 
outcomes by only including singleton pregnancies. By restricting to women without 
severe anemia at screening, and considering that malaria infection can lead to anemia, 
we likely did not enroll many women with malaria infection because they had severe 
anemia. In addition, as one of our maternal outcomes was anemia in late pregnancy, by 
excluding women with severe maternal anemia at enrollment who likely had malaria in 
the first trimester, our results were biased to find a null relationship. Finally, by excluding 
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women with hypertensive disorders at screening, we likely reduced the number of 
women with hypertensive disorders during pregnancy in our analysis population. 
Generalizability 
This dissertation study was based in three countries with varying malaria 
transmission levels and included nulliparous pregnant women with singleton 
pregnancies. Thus, our country-specific findings may be relevant to nulliparous 
pregnant women with singleton pregnancies from other areas of sub-Saharan Africa 
with similar transmission intensities. While we studied nulliparous women, over 90% of 
our study population were primigravidae. Although we studied women with the highest 
risk of malaria in pregnancy and consequent negative health outcomes, our results are 
not generalizable to women with lower risk of malaria in pregnancy (i.e., multigravidae). 
Overall, our study demonstrates how leveraging existing clinical trials can lead to 
inexpensive measurement of malaria in the first trimester which can be used to 
characterize predictors and estimate effects on maternal and birth outcomes of malaria 
in the first trimester in other study settings.  
Public Health Implications and Future Directions 
This is the first study to assess malaria in the first trimester at multiple sites, and 
we were able to determine that the prevalence of malaria in the first trimester varied by 
transmission intensity; in the DRC where the transmission intensity is high, the 
prevalence of malaria in the first trimester was also high, and in Zambia where the 
transmission intensity was low, the prevalence of malaria in the first trimester was also 
low. Consistent with previous research, lower overall educational attainment (no 
secondary education) was associated with higher prevalence of malaria in the first 
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trimester. In addition, other predictors of malaria in the first trimester varied by country, 
and malaria in the first trimester can lead to higher prevalences in preterm birth, low 
birth weight, and anemia in late pregnancy. 
As lower overall educational attainment (no secondary education) was 
associated with higher prevalence of malaria in the first trimester, public health officials 
should target ITN distribution strategies towards women with lower overall educational 
attainment. In addition, given the differences in our findings on most predictors by 
country, more research is needed to identify actionable predictors to focus interventions 
and target women at highest risk of malaria in the first trimester. In addition, the 
detrimental effects of malaria in the first trimester on preterm birth, low birth weight, and 
anemia in late pregnancy suggest that interventions should be expanded to focus on 
prevention and treatment of malaria among primigravidae women in the first trimester 
and even preconception. Examples include providing ITNs to all women before 
pregnancy instead of at the first ANC visit, shifting ANC to begin in the first trimester, 
and driving research developments on prophylactic malarial medications for use in the 
first trimester. 
Future research includes increasing sample sizes to improve power to detect 
differences in maternal and birth outcomes. In addition, more studies need to assess 
predictors of malaria in the first trimester in order to identify actionable predictors. 
Future studies should also assess predictors and the effects on maternal and birth 
outcomes of malaria in the first trimester among women of all gravidae. Finally, malaria 
in the first trimester is very common in high transmission settings despite 
implementation of current WHO recommendations of diagnosing and treating malaria, 
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IPT-SP, and ITNs, suggesting a need for stronger interventions. Future studies can 
assess detection and treatment methods of malaria in pregnancy in order to reduce the 
prevalence of malaria in the first trimester 
Using the first large-scale multi-site study of malaria in the first trimester, we were 
able to assess predictors and the effects on maternal and birth outcomes of malaria in 
the first trimester at three sites with different transmission settings. We found that 
malaria in the first trimester is very common in high transmission settings and can lead 
to higher prevalences of preterm delivery, low birth weight, and anemia in late 
pregnancy. The high prevalence of infections in high-transmission areas along with 
associations of malaria in the first trimester with higher prevalences of adverse maternal 
and birth outcomes suggest that screening women early in pregnancy may be needed 





Appendix Information for Chapter IV 
Projected gestational age at enrollment was developed from algorithm as 
previously described in Hoffman et al., 2020.19 In short, it was developed by taking the 
date of randomization, subtracting the value – projected expected delivery date (EDD) 
minus 280 days – and then dividing by 7. The definition of projected EDD varied 
depending on whether it was the same as the ultrasound EDD or the last menstrual 
period (LMP) EDD.  
The projected EDD equals to ultrasound EDD under the following conditions: (1) 
If LMP was unknown or gestational age (GA) at randomization according to LMP was 
less than zero; (2) If the GA at randomization according to LMP was between 0 weeks 
and 0 dates to 8 weeks and 6 days, and the difference between GA at randomization 
according to LMP and GA at randomization according to ultrasound was greater than 5; 
(3) If the GA at randomization according to LMP was between 9 weeks and 9 days to 13 
weeks and 6 days, and the difference between GA at randomization according to LMP 
and GA at randomization according to ultrasound was greater than 7; and (4) If the GA 
at randomization according to LMP was 14 weeks 0 days or greater.  
 The projected EDD equals the LMP EDD under the following conditions: (1) If the 
GA at randomization according to LMP was between 0 weeks and 0 dates to 8 weeks 
and 6 days, and the difference between GA at randomization according to LMP and GA 
at randomization according to ultrasound was 5 or less; and (2) If the GA at 
randomization according to LMP was between 9 weeks and 9 days to 13 weeks and 6 
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days, and the difference between GA at randomization according to LMP and GA at 
randomization according to ultrasound was 7 or less.  
The Global Network Socioeconomic Status Index was used to assess 
socioeconomic status and is calculated by determining the sum score of the number of 
10 specific items owned by the household that was converted to a country-specific SES 
score.136 These country-specific SES score range from 0 to 100.136 The mean and 
standard deviation (SD) of SES index scores were similar for the 50,000 households the 
GN SES Index was developed from and for the women included in this malaria sub-
study. For Congolese women, the mean was 11.01 and SD was 9.33 for all households, 
and the mean was 12.96 and SD was 9.61 for household included in this malaria sub-
study.136 For Kenyan women, the mean was 17.13 and SD was 18.24 for all 
households, and the mean was 16.96 and SD was 17.37.136 For Zambian women, the 
mean was 35.26 and the SD was 22.13 for all households, and the mean was 43.61 
and SD was 26.08.136 However, for all household, about one-third were nulliparous 
while in this sub-study all participants were nulliparous.   
 
Appendix Information for Chapter V 
There were 92 (6.4% of total sample) women missing data for small for 
gestational age (27 (5.8%) from DRC, 45 (7.0%) from Kenya, and 20 (6.0%) from 
Zambia), 49 (3.4% of total sample) missing data for low birth weight (11 (2.3%) from 
DRC, 33 (5.1%) from Kenya, and 5 (1.5%) from Zambia), and 195 (13.5%) missing data 
for anemia in late pregnancy (18 (3.8%) from DRC, 121 (18.8%) from Kenya, and 56 
(16.7%) from Zambia). There were no missing covariate data except for 40 (2.8% of 
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total sample) women missing socioeconomic status data (15 (3.2%) from DRC, 25 
(3.9%) from Kenya). 
Figure A.1: DAG of the relationship between the exposure of malaria in the first 
trimester and the outcome of low birth weight 
The minimally sufficient adjustment set to determine the total effect of malaria in the first 
trimester on low birth weight is season coincident with the first trimester, age, education, 
maternal socioeconomic status (SES), malnutrition (used a proxy of maternal BMI), and 






Figure A.2: DAG of the relationship between the exposure of malaria in the first 
trimester and the outcome of small for gestational age 
The minimally sufficient adjustment set to determine the total effect of malaria in the first 
trimester on small for gestational age is season coincident with the first trimester, 
maternal age, maternal education, maternal socioeconomic status (SES), malnutrition 






Figure A.3: DAG of the relationship between the exposure of malaria in the first 
trimester and the outcome of perinatal mortality 
The minimally sufficient adjustment set to determine the total effect of malaria in the first 
trimester on perinatal mortality is season coincident with the first trimester, maternal 
age, maternal education, maternal socioeconomic status (SES), malnutrition (used a 





Figure A.4: DAG of the relationship between the exposure of malaria in the first 
trimester and the outcome of anemia in late pregnancy. 
The minimally sufficient adjustment set to determine the total effect of malaria in the first 
trimester on anemia in late pregnancy is season coincident with the first trimester, age, 
education, socioeconomic status (SES), malnutrition (used a proxy of maternal BMI), 
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